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INTRODUCTION 
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Cancer registration is considered to be an essential part of any research programme 
into cancer control [1]. The main objective of a cancer registry is to collect and classify 
information on all cancer cases. These data can be used to produce statistics on the 
occurrence of cancer in a well-defined population and to provide a framework for 
assessing and monitoring the impact of cancer on the community [2]. 
By publishing incidence rates, cancer registries provide insight into the occurrence of 
cancer for clinicians, epidemiologists, the public and the government. It could be argued 
that mortality statistics already satisfy these aims, but cancer registration data are 
preferable for several reasons: 
- cancer incidence includes non-fatal cases and therefore it better represents the real 
cancer risk; 
- changes in cancer risk can be observed at an earlier time, as death from cancer may 
occur years later; 
- cancer registry data are very detailed (e.g. histology and stage), thus enabling the 
identification of trends in specific types of cancer. 
The purpose and use of cancer registries is not limited to the production of figures and 
rates alone. An equally important additional aim of recording data is to obtain clues 
about disease etiology and to support the conduct of epidemiological studies on the 
etiology of cancer, patterns of care, clinical research, health care planning and the 
evaluation of screening programmes [3]. 
The national cancer registry and most regional cancer registries in the Netherlands 
have been established only recently [3,4]. The nine regional cancer registries are kept 
by the Comprehensive Cancer Centres. Within the structure of the centres, hospitals, 
universities and radiotherapy institutes work together. The aim of the centres is to 
improve care for cancer patients. Besides cancer registration, the centres are involved 
in cancer research and treatment and coordinate regional activities on cancer pre-
vention, screening, education and psychosocial care. Together, the nine regional cancer 
registries comprise the nation-wide cancer registry in the Netherlands. 
The use of cancer registry data justifies their collection. Furthermore, in order to be able 
to use the data, they have to be of sufficiently high quality. Evaluation of the quality of 
the data recorded and the application of cancer registry data are the central themes in 
this thesis. 
Some historical notes 
An attempt to create a national cancer registry in the 1950s proved to be unsuccessful 
and funding was withdrawn in 1974. Case ascertainment of the cancer registry was 
believed to be sadly incomplete and the data were hardly ever used [5]. Only the Eind-
hoven cancer registry managed to survive, and it now forms one of the nine regional 
cancer registries in the national cancer registry. 
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The very first attempt to gain insight into cancer occurrence dates back as far as 1900 
[6] In Germany and the Netherlands, physicians were asked by letter to report informa-
tion about all the cancer patients under their care on 15 October 1900 Only an estim-
ated 60% of all Dutch physicians responded Unfortunately, the design of the study, a 
survey, hampers comparisons with current cancer incidence data. However, the 
publication provides a unique indication of the epidemiology of cancer at the beginning 
of the twentieth century. In 1900, the Dutch population was estimated at 5 000 000. Life 
expectancy at birth was only 51 years for males and 53 years for females [7]. 
Reports were received about 878 cases of cancer who were under care on 15 October 
1900. These were 372 males and 506 females. The most frequently reported sites were 
the intestinal tract (50%), breast (20%), female genital organs (13%), face (8%) and 
lower lip (4%). Compared to the distribution of incident cancer cases in 1989 [3], 
marked differences can be seen (Table 1 1). 
Table 1.1: 
Demographic background information and most frequent cancers in the Netherlands according to site and 
gender in 1900 and 1989 [3,6-8] 
1900 
Population size (million) 
Life expectancy (yrs) 
Males 
Females 
1900 
Males 
Intestinal tract 
Other sites 
Females 
Breast 
Intestinal tract 
Female genital organs 
Other sites 
Demographic 
N 
275 
97 
178 
163 
112 
53 
Most 
background information 
50 
51 0 
53 4 
1989 
Population size (million) 
Life expectancy (yrs) 
Males 
Females 
frequent cancers 
(%) 
74% 
26% 
35% 
32% 
22% 
10% 
1989 
Males 
Lung 
Intestinal tract 
Prostate 
Other sites 
Females 
Breast 
Intestinal tract 
Female genital organs 
Lung 
Other sites 
N 
7171 
6801 
4112 
11 567 
7968 
6143 
3436 
1266 
7173 
14 8 
73 7 
79 9 
(%) 
24% 
23% 
14% 
39% 
31% 
24% 
13% 
5% 
28% 
Lung and prostate cancer, the two most frequent cancers among males in 1989, were 
not mentioned at all in 1900. There are several explanations for the differences 
observed First, life expectancy in 1900 was comparatively short and the incidences of 
lung and prostate cancer are especially high in the elderly. Second, people had only 
recently become aware of the diagnostic potential of X-rays in 1900 [9] and the dia-
gnosis of lung cancer was therefore still in its infancy Nevertheless it should be realised 
that the differences can largely be attributed to lower tobacco consumption at the begin-
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ning of this century. A quarter of a century later, an increase in lung cancer mortality 
was reported [10]. 
Within the time-span of a century, the manifestation of cancer has changed dramatic-
ally. However, significant trends in time with respect to the incidence of cancer have 
also been observed in recent years. Rapid increases in the incidence of prostate cancer 
[11], lung cancer in females [12], adenocarcinoma of the lower oesophagus and cardia 
[13] and melanoma of the skin [14] have been reported. In contrast, stomach cancer 
has decreased significantly in the past few decades [15]. These more recent trends can 
probably be attributed to improved detection (e.g. prostate cancer) and/or changed 
exposure to known or unknown carcinogens (e.g., lung cancer in females and 
adenocarcinoma of the lower oesophagus and cardia). 
Quality control of cancer registry data 
Skeet stated that 'unreliable information is worse than no information at all' [16], while 
Robles judged more mildly that 'the usefulness of a population-based cancer registry 
depends to a large extent on the quality of its data' [17]. Despite the fact that these 
statements have been supported by many authors, until recently relatively few studies 
have been performed on the quality of cancer registry data [18]. In a review published in 
1980 two main aspects of the quality of registry data were distinguished: completeness 
and validity (or accuracy) [19]. 
In this part of the chapter, a brief review is made of the different types of study with 
respect to the quality of cancer registry data. Before it is appropriate to measure these 
aspects of quality, it is necessary to define the terms required to create a cancer registry 
of high quality. These terms include the use of multiple means of notifying the cancer 
registry (data sources), the establishment of data definitions, a well-maintained data 
manual and the continuous training of tumour registrars [20]. 
Completeness of coverage implies that a population-based cancer registry aims to 
register every cancer case within its catchment population. Low and inconsistent 
completeness hampers analyses of time trends and differences in cancer incidence 
between populations. Paradoxically, endeavours to achieve completeness of coverage 
may also lead to problems. First, using multiple data sources and imperfect identifica-
tion items may cause duplication of cancer cases in the database. Second, inclusion of 
non-eligible cases (e.g., cases from outside the catchment population) has to be pre-
vented. 
Several methods have been suggested to estimate completeness [19,21]: the death 
certificate method, the historic data method, the independent case ascertainment 
method and the capture-recapture method (Table 1.2). 
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Table 1.2: 
Summary of methods to the evaluate completeness of case ascertainment in cancer registries 
Method Description Comment 
Death certificate Proportion of cases reported by death Not applicable in the Netherlands, death 
certificate only certificates not made available to cancer 
registries 
Historic data Comparison of rates with histonc data or Basic assumption that differences are 
data from another population small 
Independent case Comparison of cases with the results of an Probably the most reliable method, but it 
ascertainment independent survey in the same catchment requires considerable effort 
population (preferably by linkage of individ-
ual records) 
Capture-recapture Estimation of the number of missed cases Little additional effort required, but 
by recording the notification sources of independence of notification sources 
every recorded case in the registry has to be assumed 
With the death certificate method, the proportion of cases reported by death certificate 
only is used to estimate completeness [22]. The method cannot be applied in the 
Netherlands because death certificates are not yet made available to the cancer registry 
owing to privacy regulations. Also, the estimates yielded by this method can be biased 
by a low case fatality rate and low validity of the cancer mortality data [23]. 
The historic data method compares observed numbers to data from other populations or 
to preceding years of incidence. This method assumes that differences in cancer incid-
ence between populations (and in time within the same population) are small If large 
differences are observed, this method cannot determine whether the differences are 
real or caused by registration artifacts. 
A more preferable method is independent case ascertainment, which involves com-
paring the total number of cases registered by the cancer registry to the results of an 
independent survey in the same area and over the same period [19]. If an estimate can 
be derived by linking individual records, it is probably the most reliable method for esti-
mating the completeness of a cancer registry [19]. This method, however, requires 
considerable effort and cannot be applied feasibly on a routine basis. 
Finally, the capture-recapture technique was used by the Ontario cancer registry to 
estimate completeness [17]. The technique was developed in zoology to estimate the 
size of animal populations. In different samples, animals are counted and tagged By 
counting the proportions of animals that have been tagged in other samples, the size of 
the total population can be estimated It is being used increasingly in epidemiology 
[24,25] The method is appealing because it can be applied on a continuous basis and 
little additional effort is required It is necessary that the separate data sources are kept 
of every record in the cancer registry. 
Validity is defined as 'conformity with truth or a standard or rule' [20] Accuracy is a 
combination of validity and reproducibility. Errors that introduce inaccuracy, can arise in 
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a multitude of ways: by abstraction, transcription, coding or typing errors [16] Several 
methods have been proposed to estimate accuracy the diagnostic criteria method, the 
internal consistency method and the reabstracted record method (Table 1.3) [19]. 
Table 1.3: 
Summary of the methods to evaluate the accuracy of cancer registration 
Method Description Comment 
Diagnostic criteria Proportion of microscopically confirmed Limited application 
cases 
Internal consistency Several range and inter-item consistency Only a limited proportion of errors can 
checks be prevented or detected 
Reabstracted case Reabstraction of records and comparison Measures reproducibility only 
records with routinely abstracted information 
The diagnostic criteria method is frequently applied by cancer registries [26]. The 
number of histologically or microscopically confirmed cases is calculated and tabulated 
to show the proportion of registry cases that meet a set of stringent criteria. However, 
the application of the outcome is limited. Microscopic confirmation is no assurance that 
the record does not contain errors of other kinds. 
The internal consistency method involves range and consistency checks of the records. 
Thus, a case of prostate cancer in a female will be rejected and a case of chronic 
lymphocytic leukaemia in a child can be marked as a possible error. However, this 
method does not detect all errors. For example, only a few sites of cancer are gender-
specific, and for other sites it is impossible to check validity by gender and age criteria. 
Reabstracting case records is considered to be an excellent method to estimate the 
accuracy of registry data [19]. However, only reproducibility is investigated 
Because the reabstraction process is more thorough, the reabstracted record is 
considered to be the correct one [19] Both the original and the reabstracted record 
depend on the information supplied in the medical records Information in medical 
records can be incomplete or in error, thus causing lower validity. 
Completeness and validity are two important aspects in the quality of cancer registry 
data Analysing cancer registry data can also promote the quality. 
When a Dutch researcher used bladder cancer data from one of the Scandinavian 
registries, he discovered that benign papillomas of the bladder had been recorded, but 
non-invasive bladder cancers (pTA) had not This inconsistency existed for more than 
fifteen years and not been noticed by the registry itself. 
A similar discovery was made when the cancer registry in Wales was asked to invest-
igate a possible cluster of thyroid cancer and leukaemia in the vicinity of a nuclear 
power station A review of the data obtained before the study revealed serious errors. In 
the data submitted by hospital discharge registnes, benign thyroid disease had been 
incorrectly coded as thyroid cancer Until then, these data had been in the registry 
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without any additional check. The errors would have distorted the outcome completely 
and would have suggested an erroneous excess of cancer [27,28]. 
Use of cancer registration 
The former director of the Finnish cancer registry, E. Saxén, stated that 'the sole justi-
fication of a cancer registry is .. that use is being made of its data' [29]. 
International comparison of cancer incidence data can provide clues about cancer 
etiology. The worldwide variation in cancer incidence is very high. This variation may 
give directions for the recognition of environmental causes for cancer and of means of 
prevention [30,31]. The ratio of the highest and the lowest recorded incidences is esti-
mated at 25 for lung cancer in males and 30 for breast cancer in females [26]. In Table 
1.4 the worldwide variation is shown for the ten most common cancer sites in the world 
[32]. Cancer registration also facilitates etiology studies. In case-control studies the 
cancer registry can be used to enlist all eligible cases and, sometimes, also controls [3]. 
The cancer registry can serve as an endpoint for cohort studies. Follow-up of cohort 
members without a reliable cancer registry can be extremely difficult and requires great 
effort. For this purpose a record linkage procedure has been developed that has proved 
to be highly valid and reliable [33]. 
The information stored in cancer registries can also be used for planning and setting-up 
cancer treatment and care facilities. Knowledge of trends may be used for the prediction 
of future incidence rates and needs for treatment facilities [34]. Cancer incidence data 
have been used for the planning of radiotherapy services in the Netherlands [35]. 
Research into the affect of treatment on survival and recurrence should preferably be 
studied in clinical trials. Cancer registries can serve as a sampling frame to obtain a 
representative series of patients with a specific tumour. Also, monitoring population-
based survival rates can provide insight into the effect of a new type of treatment in an 
unselected series of patients. Furthermore, cancer registration can be used to study the 
occurrence of multiple tumours in a single person and the relation with the treatment of 
the first cancer [36]. A cancer registry can also support a research project conducted by 
a regional tumour working group that is studying e.g. prognostic factors in specific 
tumour types, by collecting additional data [3,37]. These projects, generally referred to 
as documentation projects, are sometimes executed with standard registry data, but 
additional data collection may also be necessary. 
Cancer registration plays an important role in the evaluation of screening programmes. 
The effectiveness of a screening programme e.g., for cervical cancer, can be assessed 
by monitoring the incidence rates produced by the cancer registry. An effective screen-
ing programme will cause a decrease in the incidence rates of invasive cervical cancer. 
In breast cancer screening, the main endpoint is breast cancer mortality. The cancer 
registry can supply information about trends in breast cancer incidence in women who 
are not screened, shifts in stage distribution and the number of interval cancers (i.e. 
cancers diagnosed in women in the interval between two screening rounds). 
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Table 1.4: 
Worldwide variation in incidence (1983-1987) and incidence in the Netherlands (1989-1992) of the ten most 
common cancer sites in the world (rates based on fewer than 10 cases are excluded) [26,38] 
Site 
Mouth/pharynx 
Oesophagus 
Stomach 
Colon/rectum 
Liver 
Lung 
Breast 
Cervix uteri 
Prostate 
Lymphoma 
Sex 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
M 
F 
F 
F 
M 
M 
F 
Registry with 
highest rate3 
France, Bas Rhin 
55 5 
Hong Kong 
144 
France, Calvados 
26 5 
India, Bangalore 
88 
Japan, Yamagata 
93 3 
Japan, Yamagata 
42 9 
US, Hawaii Japanese 
57 4 
New Zealand Non-Maon 
42 8 
Thailand, Khon Kaen 
90 0 
Thailand, Khon Kaen 
38 3 
New Zealand Maori 
1191 
New Zealand Maori 
62 2 
US, Bay Area White 
104 2 
Peru, Trujillo 
54 6 
US, Atlanta Black 
102 0 
US, Bay Area White 
21 3 
Canada, Manitoba 
128 
Registry with 
lowest rate" 
Ecuador, Quito 
1 6 
Japan, Yamagata 
09 
Israel, Bom Afr Asia 
1 3 
Poland, rural Warsaw 
04 
India, Ahmedabad 
21 
India, Ahmedabad 
1 5 
Algeria, Setti 
20 
Algena, Setif 
2 3 
Neth .Maastricht 
08 
Neth .Eindhoven 
0 4 
Mali, Bamako 
48 
India, Madras 
1 4 
The Gambia 
3 4 
Israel non Jews 
26 
China, Qidong 
08 
Mali, Bamako 
21 
The Gambia 
1 3 
Highest 
/lowest 
ratio 
35 3 
157 
23 8 
22 1 
43 8 
28 1 
28 4 
190 
1125 
95 6 
25 0 
45 1 
30 4 
20 8 
122 8 
103 
97 
Rate3 in 
theNL 
88 
3 3 
52 
1 9 
154 
6 1 
36 3 
27 7 
1 6 
06 
73 3 
130 
80 3 
7 2 
39 6 
12 8 
86 
a) Age-adjusted incidence rates per 100 000 person-years, standardized for differences in age distribution 
using the World Standard Population 
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Structure of the thesis 
This thesis has two main sections. In the first part (Chapters 2-4) three studies are 
presented that evaluated the completeness of coverage and accuracy of cancer regis­
tration. The second part (Chapters 5-9) presents several studies that used data from the 
cancer registry and a large prospective documentation project linked to the cancer 
registry. 
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Abstract 
The completeness of cancer registration in the IKL (Integraal Kankercentrum Limburg) 
cancer registry, Limburg, the Netherlands, was evaluated for the years 1988-1990 by 
means of the independent case ascertainment method. This study was performed in 
cooperation with the Registration Network of Family Practices (RNFP) of the University 
of Limburg. The RNFP is a centralized database of general practitioners, with their 
patients' background variables and diagnoses. The contents of the two databases were 
compared using a computerized record-linkage. If the information from both databases 
differed, this was verified using the source forms of the cancer registry and the GP 
involved. By combining the information from both registries in this way it was deter-
mined which malignancies should have been registered by the cancer registry. 
The IKL cancer registry had recorded 307 of the 319 eligible malignancies (96.2%). Five 
of the 12 missed registrations could be attributed to systematic shortcomings in the 
notification procedures. The estimated completeness for all malignancies of the IKL 
cancer registry is comparable with the results from cancer registries outside the Nether-
lands which have been established for longer. 
Introduction 
Incidence rates calculated from a registry with incomplete case ascertainment can lead 
to misinterpretation of geographical differences or trends in time. Several methods have 
been suggested for testing the completeness of a registry [1]. Commonly, death certific-
ates are used to measure the completeness of a cancer registry. In this approach, 
completeness is defined as the proportion of registered cases which were not first 
identified by death certificate [1]. Cases reported by death certicate only and which have 
apparently not been reported before are an indication of incompleteness of case 
ascertainment. For non fatal cancer cases this method does not give a good indication 
of completeness. Another suggested method is the historic data method in which the 
expected number of registered cases is calculated based on the basis of known incid-
ence rates of another cancer registry. This method does not take into account the vari-
ation in time or in place of cancer incidence. Recently, the capture-recapture technique 
has been used to estimate the completeness of a registry [2]. This technique has been 
widely used in zoology to estimate the size of animal populations. It is a promising 
technique, but its usefulness still has to be demonstrated. 
A reliable method is independent case ascertainment, which involves comparing the 
total number of cases registered by the cancer registry with the results of an independ-
ent survey in the same area and for the same period. If this estimate can be derived 
from a linkage of individual records this is perhaps the most reliable method for the 
estimation of completeness of a registry [1] and several cancer registries have used this 
method [3,4]. 
This paper describes such a study on the completeness of a recently established 
cancer registry in the south-east of the Netherlands. It is one of the nine regional cancer 
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registries in the Netherlands, which together comprise the Netherlands national cancer 
registry. 
Regarding the completeness of the Netherlands Cancer Registry it was originally sug-
gested that 8-15% of the cancer cases would not be recorded [5,6]. However, a recent 
study estimated that its incompleteness was limited to only 1.3% [7]. 
Because these studies had their shortcomings, a new study was performed by the IKL 
cancer registry (IKL= Integraal Kankercentrum Limburg/ Comprehensive Cancer Centre 
Limburg) using data from an independent source. 
Methods 
The IKL Cancer registry 
The IKL Cancer registry was established in 1984. Since 1986 all nine hospitals and 
seven pathology laboratories in the region have reported to the registry. Incidence data 
for the period 1986-1988 have been published recently [8-10]. The cancer registry 
receives lists of newly diagnosed cases on a regular basis from the seven pathology 
departments in the region. In addition lists of hospitalized cancer patients are obtained 
from the medical records departments of the nine hospitals and the Radiotherapeutic 
Institute. Following this notification, the medical records of newly diagnosed patients 
(and tumours) are collected and the relevant information for the cancer registry is 
abstracted from the medical records by trained registration clerks [9]. In the cancer 
registry identifying information (i.e. name, date of birth, gender, address, postal code, 
place of birth), tumour information (i.e. topography, morphology, staging, initial therapy, 
basis for diagnosis, date of incidence) and other administrative information (i.e. date of 
death) is stored. All malignancies, including non-infiltrating malignancies, are registered, 
except basal cell carcinomas of the skin. Due to privacy regulations death certificates 
can not be used as an additional source of notification of cancer cases in the Nether-
lands. Tumour data are coded according to International Classification of Diseases-
Oncology (ICD-O) [11]. 
On 1 January 1988, the population of the IKL area consisted of 838 199 inhabitants 
(415 380 males and 422 819 females) (Source: Central Bureau of Statistics). On 
1 February 1991, the IKL Cancer registry contained information of 22 941 patients with 
cancer. 
Registration Network of Family Practices (RNFP) 
The RNFP was established by the Department of General Practice of the University of 
Limburg. It is a collaboration of 15 partnerships of General Practioners (GPs) and 
serves as a sampling frame for research [12]. However, two partnerships are located 
outside the IKL-area and their data are not used for this study. 
The GP has a central role in health care in the Netherlands. All Dutch citizens are regis-
tered with one specific general practice and treatment from a medical specialist requires 
referral from a GP. After consultation, specialists have to inform the GP of the diagnosis 
and treatment. The GPs collaborating in the RNFP have computerized their medical 
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files. Background variables and diagnoses are coded and stored in computer files. 
Every 3 months the GPs send summaries of these files to the central database of the 
RNFP [12]. In this database identification codes, not names, are included. Identification 
by name is only possible after linkage with the patient files in the individual practices. 
Diagnoses are coded according to the International Classification of Primary Care 
(ICPC) [13]. RNFP data collection was started in 1988. Medical history is coded and 
entered into the database for all patients registered with a general practice. The central 
database keeps separate files containing information on the deceased and patients who 
have moved away. In February 1991, the database contained information of 30 574 
patients living in the IKL area (3.6% of the population). Between 1988 and 1990 375 
patients had a diagnosis suggesting a possible malignancy. 
Record linkage and verification 
The record linkage between the 30 574 RNFP and 22 941 IKL records was performed in 
February 1991, after a pilot study in 1990 [14]. This study estimates completeness for 
the incidence years 1988, 1989 and 1990. A protocol developed in 1988 by the IKL 
cancer registry was used for the record linkage [15]. For record linkage date of birth, 
gender, residential postal code and place of birth were available. All adresses in the 
Netherlands have been allocated a postal code, which consists of four digits and two 
letters. In this study only the four digits were available for record linkage. About 3000 to 
5000 inhabitants have the same postal code of four digits. There are no data available 
on the uniqueness of date of birth and gender within a postal code area. The linkage 
key consisting of date of birth, gender and residential postal code has a sensitivity (i.e. 
proportion of all correct matches obtained) of 98.4% and a positive predictive value (i.e. 
proportion of reported matches that represented correct matches) of 91.1% [15]. How-
ever, due to migration, the value of this key will decrease over time. In 1988, 4.4% of 
the population in the middle and southern part of Limburg moved to another municipality 
and thereby a different residential postal code [16]. There are no data on migrations 
within municipalities and hence changes in residential postal code. The identifying 
information for linkage is presented in Table 2.1. 
After record linkage the tumour information (e.g. topography, morphology, date of incid-
ence and treating specialist) and the place of birth on the IKL record was compared with 
the information in the RNFP record. If this information was in agreement, the matched 
records were considered to be identical. If a RNFP record with tumour information and 
an incidence year since 1988 could not be linked to an IKL record, a second linkage 
was performed with a part of the linkage key (e.g. year of birth excluded), to eliminate 
the possibility of a negative match due to an error in the identifying information. If after 
this second linkage the record still could not be linked to an IKL record, the information 
was verified with the GP. In addition, if an IKL record (with tumour information) had 
been linked with a RNFP record without a cancer diagnosis, the information was verified 
with the GP and the IKL (check of original cancer registry forms and if necessary, con-
sultation with hospital administration). 
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Table 2.1: 
Available identifiers for linkage in the Registration Network of Family Practices (RNFP) and the Comprehens­
ive Cancer Centre Limburg (IKL) cancer registry file 
Percentage availability 
Identifier 
Date of birth 
Place of birth 
Gender 
Residential postal code 
RNFP file 
% 
100 0 
95 2 
100 0 
99 1 
IKL registry0 
% 
100 0 
41 2" 
100 0 
95 0 
a) Percentages for all registrations with incidence year 1966-1990, b) Because of hospital registration prac­
tices in the Netherlands 
Finally, a number of additional RNFP records were added to the records that had to be 
verified as an extra check for the validity of the linkage procedure. These records did 
not contain any cancer-related diagnosis and were not linked to any IKL record. If the 
linkage procedure has been performed well, then no cancer should be found in these 
records. These records were selected for a related study on epilepsy, with all age cat­
egories represented. In Figure 2.1 the linkage procedure is shown schematically. 
Verification of disagreements regarding tumour information was performed by contact­
ing the G Ρ involved. The GP was asked to provide explicit information with regard to the 
presence and type of cancer. In this way we were able to determine whether the case 
matched the criteria for cancer registration. Malignancies (including non-infiltrating), 
diagnosed between 1988 and 1990 and living at the time of diagnosis within the IKL 
area, were included. Borderline lesions or basal cell carcinomas of the skin were 
excluded. Because neither the IKL or the RNFP registry can be assumed to be com­
plete a prion, the information from both registries and from the verification phase was 
combined to determine which malignancies from the populations of the general prac­
tices should have been registered by the IKL cancer registry. The RNFP cases that 
were not recorded by the IKL cancer registry were analysed for possible reasons for 
failure. 
Results 
The linkage 
The linkage between the IKL registry and the RNFP database resulted in 315 linked 
records with regard to the identifying information (Figure 2.1). Of these, 241 patients 
with 267 malignancies had a cancer diagnosis in both registries. For the other 74 
patients with 74 malignancies the identifying information was identical but the RNFP file 
did not contain a cancer related diagnosis. These diagnoses could have been missed 
by the RNFP or were false positive matches. 
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I KL database 
22941 records 
RNFP database 
30574 records 
RNFP records linked 
with IKL records 
P=315 
RNFP records not 
linked with IKL 
P=30259 
RNFP 
records 
with 
cancer 
P=241 
T=267 
RNFP 
records 
without 
cancer 
P=74 
tumour 
identical? 
P=285 
T=311 
YES Ï 
-ГЛ 
RNFP 
records 
with 
cancer 
P=136 
Ï 
sample 
of other 
RNFP 
records 
P=288 
second linkage 
with less specific 
key 
linked with 
IKL-record 
P=44 
NO P=24 
other 
P=92 
No verification 
P=274 T=287 
eligible for 
study 
T=250 
ï 
Verification with General Practitioner 
and IKL forms P=478 
Ώ 
not eligible 
for study 
T=37 
Results of verification 
see table 2 31 
eligible for 
study 
T=69 
E 
not eligible 
for study 
T=409 
Figure 2.1: Scheme for record linkage of RNFP and IKL file 
T=Tumour; P=Patient. 
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In all 136 patients were known with cancer in the RNFP database and had an incidence 
year from 1988 onwards but could not be linked to a record in the cancer registry. Link-
age with a part of the linkage key (excluding the postal code, or year of birth, or month 
of birth, or day of birth or gender one by one) resulted in the linking of an additional 44 
patients with 44 malignancies. In 38 of these 44 cases, the postal code was missing in 
one of the records or differed due to a migration. The remaining 92 RNFP records with 
cancer (that were linked to an IKL record) were verified with the original source of the 
information. 
The 241 patients with 267 malignancies that were linked between the IKL and the RNFP 
databases and that contained a cancer-related diagnosis in the RNFP record, were 
compared 'manually' for agreement. In addition, the 44 patients with 44 malignancies 
that were matched with a part of the linkage key were also extensively checked. Of the 
total of 311 malignancies 24 had discordant information and had to be checked with the 
original source of the information. 
As a control group 288 patients were added to the enquiry as a sample of the 
unmatched records to check the validity of this part of the linkage. In total, 478 forms 
were sent to the GP's to obtain information with respect to the (presence of) cancer. In 
all 464 forms were returned, leaving 14 forms for which the GPs could not find neces-
sary information. The procedure is summarized in Figure 2.1. 
Results of the verification 
The results of the verification are summarized in Table 2.2, where the verified records 
are separated according to the outcome of the verification and the eligibility for cancer 
registration in this study. Reasons for non eligibility are a diagnosis of basal cell 
carcinoma of the skin or a year of incidence before 1988 or after 1990. For the former 
eligibility could only be determined afterwards, because the ICPC code for skin cancer 
does not discriminate between melanoma and basal cell carcinoma. In the verification 
phase it also appeared, that in the RNFP records, recurrence was sometimes coded as 
a primary cancer, and that the true primary cancer was diagnosed before 1988. 
In the sample of 288 control records no cancer was known to the GP for 276 cases. 
Only one patient in this group was known to have cancer by his GP and this cancer had 
been diagnosed many years before 1988 and could not have been recorded by the IKL 
cancer registry. For 11 patients the GP could not find the necessary information. 
Of the other 190 patients that were verified by the GPs, 66 tumours were not registered 
by IKL. Of these 66, 54 were not eligible for this study. Some 40 cases had not been 
recorded by the RNFP (of which 37 were eligible). For another 23 cases the difference 
in coding could be attributed to coding errors in the RNFP (four eligible for this study). In 
seven cases the correct match was found after the verification (three are eligible). A few 
cases (N=15) were notified to the cancer registry after 1 February 1991. For the majority 
of these cases the year of incidence was 1990. The explanation is the delay in the 
delivery of the information from medical records departments. For 14 cases the GP 
could not find the necessary information of which 11 came from the control group. In 
total, of the 478 records that were verified by the GPs 69 were eligible for cancer 
registration in this study. 
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Table 2.2: 
Results of the verification procedure with General Practitioners 
eligible * for cancer registration 
in the period 1988-1990. 
Result of venfication Yes 
37 
4 
3 
-
-
13 
12 
-
69 
No 
3 
19 
4 
276 
37 
2 
54 
14 
409 
Total 
40 
23 
7 
276 
37 
15 
66 
14 
478 
Case missed by RNFP 
Coding error by RNFP 
Correct match found after venfication 
No cancerb 
False positive matchc 
Notified to cancer registry after 
1 February 1991 
Case not recorded by IKL 
Not found by GP 
Total 
a) not included are θ g basal cell carcinoma of the skin, incidence year before 1988 or patient not known with 
cancer (see text); b) cases from the sample of the RNFP records that were not linked to an IKL record and did 
not contain a cancer related diagnosis; c) people with identical record linkage key (date of birth, gender, 
residential postal code), but after venfication not considered to be a correct match. 
The IKL cancer registry had missed 12 malignancies that were eligible for this study. 
Two were diagnosed by a medical specialist, but without clinical admission or a patho­
logical examination. One patient was only treated by the GP and was never referred to 
a medical specialist. Two patients were treated outside the IKL area (one abroad and 
one in a Dutch hospital outside the IKL area). Seven patients were clinically admitted 
and/or the malignancy was pathologically verified. These malignancies should have 
been notified to the IKL cancer registry. This suggests some problems in the notification 
procedures. 
Characteristics of the completeness 
After the linkage and the verification it was determined, which malignancies should have 
been registered by the IKL Cancer registry. The information from both databases and 
the verification procedure were combined and the tumour data were coded according to 
ICD-O. Of the 274 patients with 287 malignancies with identical information in the IKL 
and the RNFP records 250 malignancies were eligible for this study. The other 37 
malignancies could be excluded because of the incidence year (before 1988) or the 
morphology (basal cell carcinoma of the skin). Of the 478 patients verified by GPs 69 
had a malignancy eligible for this study. It was therefore concluded that 319 malig­
nancies should have been registered by the cancer registry. Of these 319 malignancies 
270 (84.6%) were registered by both registries, 37 only by the IKL cancer registry and 
12 only by the RNFP. Overall, the IKL cancer registry had recorded 307 of the 319 
eligible malignancies (96.2%) in the period 1988-1990 (95% confidence interval (CI): 
93.5-98.0%). 
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Table 2.3: 
Completeness of the cancer registry according to year of incidence 
Year of incidence 
1988 
1989 
1990 
Total 
Number of eligible 
malignancies 
N 
81 
112 
126 
319 
N 
75 
109 
123 
307 
Malignancies registered 
by the IKL registry 
% 
92 6 
97 3 
97 6 
96 2 
In Table 2.3, 2.4 and 2.5 the characteristics of the completeness are summarized. Com­
pleteness in 1988 is lower (92.6%) than in 1989 and 1990 (97.3 and 97.6% respect­
ively). Completeness varies by groups of tumour site (Table 2.4). Completeness is low 
for haematological malignancies (60%, N=5), male genital cancer (88.8%, N=18) and 
melanoma of the skin (83.3%, N=6). Completeness for e.g. malignancies of the brain 
and unknown primary malignancies is 100%. It should be stressed however, that the 
numbers are small. Completeness is similar for infiltrating malignancies (96.2%) and 
non-infiltrating (m-situ) malignancies (96 2%). The completeness for non-microscopic-
ally confirmed malignancies is rather low (three out of six). 
Table 2.4: 
Completeness of the cancer registry according to primary site 
Number of eligible Malignancies registered 
malignancies by the IKL registry 
Pnmary site 
Head, neck cancers 
Digestive tract 
Respiratory tract 
Squamous cell skin cancer 
Melanoma of the skin 
Breast cancer 
Gynaecological cancer 
Male genital cancer 
Urinary tract 
Brain 
Endocrine glands 
Malignant lymphoma 
Haematological malignancies 
Unknown pnmary and other 
Total 
N 
8 
72 
46 
15 
6 
56 
23 
18 
35 
6 
6 
14 
5 
9 
319 
N 
8 
71 
44 
14 
5 
55 
22 
16 
34 
6 
6 
14 
3 
9 
307 
% 
100 0 
9Θ6 
95 6 
93 3 
83 3 
98 2 
95 7 
68 8 
97 1 
100 0 
100 0 
100 0 
60 0 
100 0 
96 2 
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There is no clear relation between the patients' age and the completeness of the cancer 
registry (Table 2.5). The only patient with cancer below the age of 10 years was not 
recorded by the IKL cancer registry. Above the age of 80 years the completeness does 
not decline. Between males and females there is only a small difference in complete-
ness of the cancer registry. 
Table 2.5: 
Completeness of the cancer registry according to age group and sex 
Number of eligible Malignancies registered 
malignancies by the IKL registry 
Ñ Ñ % 
Age group (years) 
0-9 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80+ 
Gender 
Male 
Female 
Total 
1 
2 
9 
13 
38 
51 
82 
86 
37 
167 
152 
319 
0 
2 
8 
13 
38 
48 
80 
82 
36 
160 
147 
307 
00 
100 0 
88 9 
100 0 
100 0 
941 
97 6 
95 3 
97 3 
95 8 
96 7 
96 2 
Discussion 
In this study we evaluated the completeness of the case ascertainment of the IKL 
Cancer registry by record linkage with a registry of GPs. This method is probably the 
best method for measuring the completeness [1]. However its success is largely 
dependent upon the reliability of the record linkage. The RNFP provided an attractive 
opportunity to compare its data with the IKL cancer registry, because the data are 
collected completely independent from the IKL registry. 
In this study we used a record linkage protocol developed for use by the Dutch cancer 
registry for epidemiological research [15]. Date of birth, gender and postal code were 
used as the key for record linkage. According to the earlier study, this key has a sensit-
ivity of 98.4% and a positive predictive value of 91.1 % [15] According to the protocol we 
increased the sensitivity by linking with parts of the key. The positive predictive value of 
the linkage key in the current study was only slightly lower (88.3%). 
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Verification of the matches, with help of the GP and the original cancer registry forms 
enabled us to eliminate false positive matches There is a possibility that a GP over-
looked the presence of a malignancy and a correct match was incorrectly judged as 
false positive. But if this error has occurred, it would only have led to a lower number of 
registrations in both the numerator and the denominator of the completeness percent-
age. The effect of these overlooked positive matches would be a lower estimate of the 
completeness than in reality. 
In contrast, the possibility that a false negative match has been overlooked is small. All 
patients with a cancer code in the RNFP database, who were not linked to a record in 
the cancer registry, were considered as potentially missed cases by the cancer registry. 
This was only changed, if for example the verification made it clear that the case did not 
meet the criteria for cancer registration. 
Finally, in the control group no cancer was detected that should have been recorded by 
the IKL cancer registry. We therefore assume that the outcome of the record linkage is 
reliable. 
The GP performs a key role within the health care in the Netherlands. The GP will be 
informed by the medical specialist about his patients with respect to diagnosis and 
treatment. The GPs collaborating in the RNFP will code this information and enter it into 
the computer. However, this study revealed that the RNFP missed several cases. This 
could be attributed to several coding errors. Also, cancer diagnosed at an autopsy was 
missed sometimes by the RNFP. 
The linkage was conducted at a patient level, however the cancer registry is concerned 
with malignancies and some patients had more than one (e.g. a patient with stomach 
and prostate cancer). In fact there were 307 patients with 319 eligible malignancies 
For all cancers (excluding basal cell cancer of the skin) the observed completeness of 
the cancer registry was 96.2%. 
The methods of cancer registration in the Netherlands will lead to some systematic 
incompleteness. Patients treated by the GP only, patients treated ambulatory without 
pathological diagnosis and patients treated abroad will generally not be recorded by the 
cancer registry. However, this systematic underregistration seems to be limited. Only 
five out of the 12 missed cases could be attributed to these reasons (1.6% of all eligible 
cases) 
Earlier warnings from GPs that the Netherlands Cancer Registry will have a high incom-
pleteness because of the systematic deficiencies in the notification procedures, seem to 
be unjustified [5,6]. This study confirms the results of a study of another regional Cancer 
Registry in the Netherlands which estimated systematic incompleteness at 1.3% [7] 
The seven missed cases should have been notified to the IKL cancer registration. It is 
conceivable, that these cases are not registered due to occasional errors in notification 
procedures. Most cases have multiple notifications and over time some of the missed 
notifications will be detected. 
There seems to be a relation between completeness and the year of incidence. Com-
pleteness increased from 92.6% in 1988 to 97.6% in 1990. The first year that the IKL 
cancer registry was presumed to be complete was 1986 and errors in notification 
procedures can most often be expected to occur at the start. The general incidence 
rates of the IKL Cancer Registry have been fairly constant since 1986 [8,9]. Also, some 
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correct matches may be missed because of migration and hence changes in postal 
codes. This may have occurred in the first year especially. 
Completeness is not associated with gender or age, with the exception of very young 
patients The IKL cancer registry area does not have any specialised centre for child­
hood cancer. Any such children would often be referred to such a centre after the first 
suspicion of malignancy. It was therefore anticipated that the IKL Cancer registry might 
be incomplete for childhood malignancies [8,10]. However, since 1989 all regional 
cancer registries in the Netherlands are fully operational and data will be submitted to 
the Netherlands Cancer registry. From 1989 onwards, it has been possible to exchange 
information on patients who are treated outside the area of the own regional cancer 
registry [17]. At the time of this study this exchange had not yet been effected. 
However, because of the low numbers a further study is warranted to allow more definit­
ive conclusions. 
The estimate of completeness for the IKL Cancer registry (96 2%) is comparable to that 
of other registries outside the Netherlands which have established longer. Using the 
same method in north-west England completeness of cancer registration was estimated 
at 94% [3]. Completeness of the registration of cervical cancers in Denmark was 
estimated at 97.8% [4]. For all malignancies completeness in the Danish cancer registry 
was estimated at 96.2% [18]. In the Ontario Cancer Registry the completeness was es­
timated around 95% after using the capture-recapture technique [2]. 
It should be noted that the IKL cancer registry is the only one of those mentioned regis­
tries that does not have access to death certificates. Malignancies notified by death 
certificate are an important means for many registries to improve the completeness [19]. 
Despite the lack of this notification source, the infrastructure of the Netherlands health 
care and the notification procedures used have made it possible to establish a cancer 
registry with high completeness in a short time. 
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Abstract 
Background: In this paper we investigated whether the capture-recapture method is 
useful for a cancer registry to monitor its completeness of case ascertainment on a 
routine basis. 
Methods: The capture-recapture method was used to estimate the completeness of 
case ascertainment in three regional cancer registries in the Netherlands, which are 
based on case finding by pathology laboratories and hospitals. 
Results: Completeness was estimated to be 98.3%. The estimate of completeness was 
dependent on age and cancer site, with lower estimates of completeness for skin can­
cer and lymphatic and haematopoietic malignancies and for the age group > 75 years. 
Conclusions: A major drawback of the capture-recapture method is its inability to estim­
ate the number of cases that are not routinely notified to the registry by one or both 
notification sources. Another limitation is the lack of statistical power to detect in­
completeness in an early stage. It is concluded that the capture-recapture method is not 
useful for everyday surveillance of completeness in cancer registration. 
Introduction 
Completeness of cancer registration is important because (selective) incomplete case 
ascertainment may lead to misinterpretation of trends in time and place. It can also 
cause bias in epidemiologic research based on the registry. Several methods have 
been proposed for testing completeness [1]. The most reliable method is independent 
case ascertainment, which involves linkage of individual records from the cancer regis­
try with the records of an independent survey in the same catchment area and time [1]. 
This, however, requires considerable effort and it is not feasible to apply the method on 
a routine basis. In zoology a method has been developed to estimate the size of wildlife 
populations, ι e. the capture-recapture method. In different samples animals are 
counted and tagged. By counting the proportions of animals that have been tagged in 
other samples, the size of the total population can be estimated. This method has also 
been used in epidemiological studies to estimate the prevalence of a disease [2-4]. 
Recently, the capture-recapture method was used to estimate the completeness of a 
cancer registry [5]. In this study we investigated whether the capture-recapture method 
is useful for a cancer registry to monitor its completeness of case ascertainment on a 
routine basis. For this study the 1990 data from three regional cancer registries in the 
Netherlands were available for analysis. 
Methods 
The cancer registries 
The regional cancer registries of the Comprehensive Cancer Centres, IKL (located in 
Maastricht), IKMN (Utrecht) and IKO (Nijmegen) were established in 1984, 1985 and 
Capture-recapture method 27 
1986, respectively. These three registries cover a total population of 3.3 million inhabit­
ants. From 19Θ9 onwards, all hospitals and pathology laboratories in the regions are 
participating in (one of) these registries. 
The cancer registries receive lists of newly diagnosed cancer cases on a weekly basis 
from the pathology departments in the regions. In addition, lists of discharge diagnoses 
of hospitalized cancer patients are obtained from the hospitals. These reporting pro­
cedures are computerized for the greater part. Following these notifications, the medical 
records of newly diagnosed patients (or tumours) are collected and the relevant in­
formation for the cancer registry is abstracted from the charts by trained registry person­
nel. All malignancies, including non-invasive malignancies, are recorded, with the 
exception of basal cell carcinomas of the skin and non-invasive cervical cancer. 
From January 1990 onwards, the sources of notification were recorded for each tumour 
record. Possible sources were pathology department (PA), hospital medical record 
department (MR) and other sources (OS), e.g. radiotherapy department. Because the 
number of records reported by OS only was very small (N=30), such records were 
excluded for this study. In addition, only a patient's first malignancy was selected for 
analysis. Due to shortcomings in the automatic processing of the MR notifications, the 
MR source for second (and subsequent) malignancies was not accurate. 
The capture-recapture method 
In 1990, in the catchment areas of the regional cancer registries IKL, IKMN and IKO an 
unknown number of patients were diagnosed with a first primary malignancy. Every 
patient had a certain probability of being entered into the pathology registration system 
(PA) and a certain probability of being entered into the hospital discharge system (MR). 
The cancer registries combined both data sources in order to achieve complete 
ascertainment. However, for a number of reasons, some patients were registered 
neither in PA nor in MR. Therefore, instead of cancer incidence N, an incomplete 
number of cases, Τ was registered by the registries. 
Simple analysis. In order to estimate the extent of completeness by the cancer registries 
the capture-recapture method, as described in Bishop et a/was applied [6]. With this 
method, all records in the cancer registries are classified according to source of notifica­
tion: PA+MR+, PA+MR- and PA-MR+, respectively. If notification by PA does not influ­
ence the chance of being notified by MR (and vice versa), the number in the PA+MR+ 
cell is hypergeometrically distributed, conditional on the number of records captured by 
each of the notification sources. Consequently, the total number of eligible cases can be 
estimated by ((a+b)x(a+c))/a and the number of cases not registered can be estimated 
by bxc/a (where a stands for the number of records with PA+MR+ notification, b for 
PA+MR- notification and с for PA-MR+ notification). 
Modelling. The proportion of completeness can be estimated for different sites, ages 
etc. In that case, it may be more efficient to use a modelling approach. With such an 
approach, a log-linear regression model is chosen which adequately represents the 
observed data with one or two of the notification sources. The choice of the model is 
based on goodness of fit, including the distributions of residuals and the residual 
deviance (-2 log-likelihood for Poisson probability distributions). The two-way interaction 
terms were chosen from all the remaining two-way interaction terms, not included in the 
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current model, with the highest change in deviance divided by degrees of freedom. If 
the new model was significantly better than the current model, the interaction term was 
added to the model. If the model fit was good, we found a satisfactory model, otherwise 
we had to repeat this method to look for an additional two-way (or three-way) interaction 
term. When we finally found a satisfactory model, redundant two-way interaction terms 
were deleted. After model selection, the resulting parameter estimates and interaction 
terms can be used to estimate the stratum-specific numbers of unregistered cases with 
cancer. Comparable to the more simple analysis mentioned above, in the modelling 
approach it is assumed that the data sources are independent. It is possible to include 
a cross-product interaction term of the data sources in the model, but the parameter for 
such a term will be aligned with zero because there are no observations with PA-MR-. 
For formulae calculating confidence intervals for both the simple method and the 
modelling approach we referto Robles étal[5]. 
In the analyses, both methods were used to estimate the completeness of the cancer 
registry. In the simple method the number of missed cases was calculated by summa-
tion of the number of missed cases per stratum, because of the phenomenon that the 
capture-recapture estimates can vary in subgroups because of 'variable catchability' [7]. 
In the log-linear regression analyses, the observed data were modelled as a function of 
data source (MR and/or PA), primary site, age (<65, 65-<75 and >75 years) and cancer 
registry (IKL versus IKMN versus IKO). According to anatomical localization, the primary 
sites were combined into 11 groups. Site, age group and registry-specific strata with an 
empty cell (no records with only-PA or only-MR notification) were excluded, because the 
zero from the empty cell could not adequately be modelled. For model fitting, the statist-
ical program GLIM was used [8]. 
Results 
In total, the regional cancer registries IKL, IKMN and IKO recorded 12 570 primary 
malignancies which were diagnosed in 1990. Of these, 1957 were excluded because 
the malignancy was not the first primary (N=1078), because some strata had no records 
reported by ΡΑ-only or MR-only (N=849) or because the notification was from a source 
other than PA and MR (N=30). Thus, 10 613 records were available for analysis. 
In Table 3.1 the distribution of these malignancies is shown according to regional regis­
try and notification source. In total, 809 malignancies (7 6%) were notified by MR alone, 
1673 (15.8%) malignancies by PA alone and 8131 malignancies (76.6%) by both PA 
and MR. 
Using the simple method the number of missed cases was estimated to be 187. Com­
pleteness was estimated to be 98.3%. In Table 3.2 the results are shown, according to 
site, age group and cancer registry. Completeness varied by site from 92.9% for skin 
malignancies (excluding basal cell cancer) to 99.7% for cancer of the breast. The regis­
tries' completeness was estimated to be somewhat lower for cases > 75 years (96.9%). 
In the log-linear models, the two sources of notification, age, site of malignancy and 
cancer registry were entered. The model contained parameters for the eleven site 
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groups, the three cancer registries, the three age groups and the two data sources, as 
well as one two-way interactions and three three-way interactions (Table 3.3). 
The results using the modelling approach were similar to those from the simple analysis 
(Table 3.2). Also, for the various strata the difference in estimates for completeness 
estimates between the two methods did not exceed 0.1%. 
Table 3.1: 
Distribution of first primary malignancies diagnosed in 1990 according to cancer registry and source of 
notification 
MR" only PA" only MR" and PA" Total 
cancer registry 
IKL 
IKMN 
I KO 
Total 
r 
217 
221 
371 
Θ09 
% 
76 
6 1 
9 0 
76 
r 
387 
597 
689 
1 673 
% 
13 6 
165 
166 
158 
V 
2 248 
2 803 
3 080 
8 131 
% 
78 8 
77 4 
74 4 
76 6 
V 
2 852 
3 621 
4 140 
10613 
a) MR= Notification by a medical records department of a hospital, b) PA= Notification by a pathology depart­
ment, c) T= Number of recorded malignancies 
Table 3.2: 
Estimated completeness according to site, age group and cancer registry 
Category 
Site 
Oral cavity and 
upper respiratory tract 
Gastrointestinal tract 
Deep-seated digestive organs 
Bronchus, lung and pleura 
Skin 
Breast 
Female genital organs 
Male genital organs 
Urinary tract 
Lymphatic/haematopoetlc tissue 
Other sites and unknown primary 
Age groups 
<65 years 
65-<75 years 
>75 years 
Cancer registry 
IKL 
IKMN 
I KO 
Total 
Total 
Τ 
224 
2 037 
416 
1 686 
478 
1 687 
746 
863 
963 
706 
807 
4 655 
ЗОЮ 
2 948 
2 852 
3 621 
4 140 
10613 
Simple 
99 2 
99 3 
97 5 
981 
92 9 
99 7 
99 3 
98 6 
99 4 
95 2 
96 4 
98 9 
98 7 
96 9 
98 6 
98 5 
97 9 
98 3 
% completeness (95% CI) 
analysis 
97 9-100 
99 0-99 7 
95 6-99 5 
97 4-98 9 
87 2-99 5 
99 4-100 
98 7-100 
97 7-99 6 
98 9-100 
93 3-97 3 
94 8-98 1 
98 5-99 3 
98 3-99 2 
95 7-98 1 
98 1-99 1 
97 7-99 2 
97 1-98 6 
97 9-98 7 
Modelling approach 
99 3 
99 3 
97 5 
98 1 
93 0 
99 7 
99 4 
98 6 
99 4 
95 3 
96 5 
98 9 
98 7 
96 9 
98 6 
98 5 
97 9 
98 3 
98 6-100 
99 1-99 6 
95 5-99 5 
97 6-98 8 
87 0-99 9 
99 6-99 9 
99 0-99 8 
98 0-99 2 
99 1-99 7 
93 5-97 1 
95 2-97 9 
98 5-99 3 
98 3-99 1 
95 8-98 1 
98 1-99 2 
97 8-99 2 
97 2-98 6 
97 9-98 7 
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Table 3.3: 
Choice of model for assessing the completeness of the cancer registry 
Model3 
Main effects only 
(1)s + r + a + pa + mr 
Adding 2-way interactions 
(2) + s mr 
(3) + s pa 
(4) + s a 
(5) + a pa 
(6) + s r 
(7) + r pa 
(8) + a mr 
Adding 3-way interactions 
(9) + s a mr 
(10) + s r mr 
(11) + s rpa 
Deleting redundant 2-way 
interactions, final model 
s + r + a + pa + mr + apa + 
s a mr + s r mr + s r pa 
deviance 
2 705 9 
1 560 4 
1 060 4 
527 7 
438 3 
338 1 
301 0 
269 8 
206 8 
155 8 
1197 
1197 
dfb 
244 
234 
224 
205 
203 
184 
182 
180 
161 
140 
121 
121 
Fit 
Ρ 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 009 
0 170 
0 517 
0517 
Difference from 
previous model 
deviance 
— 
-1 145 5 
-500 0 
-532 7 
-89 4 
-100 2 
-371 
-31 1 
-63 0 
-51 0 
-36 1 
-
df 
-
-10 
-10 
-19 
-2 
-19 
-2 
-2 
-19 
-21 
-19 
-
Test against 
previous 
model 
Ρ 
— 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 000 
0 010 
-
a) used terms in model s = site, г = registry, a = age group, pa = notification by pathology laboratory, 
mr = notification by medical records department, s a = interaction factor of site and age group, b) df= degrees 
of freedom 
Discussion 
In this study we used capture-recapture methods to estimate the completeness of three 
regional cancer registries in the Netherlands. The results indicate a very high degree of 
completeness, estimated at 98.3%. The estimates of completeness were the lowest for 
malignancies of skin, lymphatic and haematopoietic tissue and other or unknown sites. 
These results are as expected Skin malignancies are treated relatively frequently in 
outpatient clinics, and will then be reported by the pathology department only. The 
chance that an error in the notification procedure will lead to a missed case for cancer 
registration is therefore higher. Haematological malignancies are not always diagnosed 
by pathologists (but by a haematologist or an internist), which leaves the medical 
records department as the only notification source for a substantial part of these 
tumours. 
We compared the simple method with a log-linear regression model and found the 
differences between the results were small which confirmed the results of Robles [5]. 
The capture-recapture method is only capable of estimating the number of malignancies 
that could have been notified by pathology laboratories or hospitals. Although in general 
Capture-recapture method 31 
the notification procedures were handled automatically, notifications may have been 
missed For example, it appeared that some of the notifications from the medical 
records departments concerned malignancies with microscopic verification, but for 
some reason they were not entered into the cancer registry database. This was prob-
ably due to administrative errors at the pathology laboratory or the cancer registry itself 
In the Netherlands two studies have estimated the completeness of the cancer registry 
using the independent case ascertainment method [9,10] Berkel estimated the pro-
portion of missed cases (known only to the general practitioner) at 1 3% [9]. In a study 
of the IKL cancer registry this proportion was estimated at 1 8% [10]. The missed cases 
in those studies had an almost zero chance of being notified to the cancer registry by 
pathology laboratories or hospitals. Therefore, the number of cases that were seen by 
the general practitioner only, or were treated abroad, could not be estimated with the 
capture-recapture method. By analogy, when zoologists use the capture/recapture 
method in a nature reserve, they do not pretend that they can estimate the number of 
animals living outside the fences of the nature reserve. 
From the IKL study [10], the proportion of missed cases that were omitted due to errors 
in the notification procedures could also be calculated This proportion amounted to 
2 2% [10]. This result was only slightly different from the estimate of the present study 
for the IKL cancer registry: 1.7%. 
The capture-recapture method has been proposed by several authors for estimation of 
the completeness of prevalence studies or cancer registries [2,4,5]. The method is 
dependent on the assumption that the errors in notification sources are not correlated. 
If this assumption does not hold, it will influence the estimate of the unknown number of 
missed cases. Whether or not the two notification sources in this study (PA and MR) 
were dependent, could not be derived from the analysis, because there were no known 
observations with PA-MR-. Even if a third notification source had been available, 
independence of the three notification sources cannot be proven either. The three-way 
interaction term in the modelling approach will remain unknown [11] 
However, the pathology laboratories and medical records departments are operated 
independently and the most likely explanation for missed registrations is, therefore, the 
existence of (uncorrelated) errors in the notification procedures. 
If the sources are positively correlated, the completeness will be overestimated, and 
vice versa. The correlation of errors can be expressed as the odds ratio (axd/bxc) [4]. 
When independence is assumed, the odds ratio is fixed at 1. In Table 3.4 the relation 
between the odds ratio and the estimate of completeness is shown. 
Completeness (%) 
99 1 
98 3 
97 4 
96 6 
95 8 
95 0 
Total 
95% Confidence Interval 
98 9-99 4 
97 9-98 7 
96 9-98 0 
95 9-97.3 
94.9-96 7 
94 0-96 0 
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Table 3.4: 
Influence of correlated errors (dependence) in the notification sources (for several odds ratios) on the estimate 
of the completeness 
Odds ratio 
05 
1 0 
1.5 
2.0 
25 
3.0 
In our opinion, the capture-recapture method is not a useful tool for monitoring the 
completeness of cancer registration on a routine basis. In contrast to the independent 
case ascertainment method, financial and personnel expenses are limited. However, 
the method will be useful only if it can be used for different sites, age groups, hospitals, 
etc. In general, deficiencies in notification procedures will occur in specific hospitals and 
perhaps also for specific sites. The number of strata in such an analysis will then be 
much larger than in the current study. Because of the limited numbers in the strata, the 
power of the method will become insufficient to detect deficiencies in notification pro­
cedures at an early phase. It is therefore concluded, that the capture-recapture method 
is not useful for everyday surveillance of completeness. 
References 
1 Goldberg J, Gelfand HM, Levy PS Registration evaluation methods' a review and a case study 
Epidemiol Rev 1980, 2 210-20 
2 Wittes JT, Colton T, Sidel VW Capture-recapture methods for assessing the completeness of case 
ascertainment when using multiple information sources J Chron Dis 1974, 27 25-36. 
3 Neugebauer R Application of a capture-recapture method (The Bernoulli! census) to historical 
epidemiology Aw J Epidemiol 1984,120 626-34 
4. Hook EB, Regal RR. The value of capture-recapture methods even for apparent exhaustive surveys 
Am J Epidemiol 1992,135' 1060-7. 
5. Robles SC, Marrett LD, Clarke EA, Risch HA. An application of capture-recapture methods to the estima­
tion of completeness of cancer registration. J Clin Epidemiol '\9B9, 41. 495-501. 
6. Bishop YMM, Fienberg SE, Holland PW Discrete Multivariate Analysis Theory and Practice Cambridge, 
MA , MIT Press, 1975 
7 Hook EB, Regal RR effect of variation in probability of ascertainment by sources ('variable catchabihty') 
upon "capture-recapture" estimates of prevalence. Am J Epidemiol 1993.139,1148-66. 
8. Baker RJ, Neider JA. The GUM system, Rev 3,77 Oxford, Numerical Algorithms Group, 1985. 
9. Berkel J General practitioners and completeness of cancer registry. J Epidemiol Comm Health 1990; 44: 
121-4 
10. Schouten LJ, Hoppener Ρ, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer regis­
tration in Limburg, the Netherlands Int J Ep/dem/o/1993, 22 369-76. 
11. Kiemeney LALM, Schouten LJ, Straatman Η. Ascertainment corrected rates (Letter to the editor) Int J 
Epidemiol 1994; 23 203-4. 
CHAPTER 4 
QUALITY OF CANCER REGISTRY DATA: 
A COMPARISON OF DATA PROVIDED BY CLINICIANS 
WITH THOSE OF REGISTRATION PERSONNEL 
L.J. Schouten, J.J. Jager, P.A. van den Brandt 
Br J Cancer 1993; 68: 974-977 
by permission of Macmillan Press Limited 
34 Chapter 4 
Abstract 
The quality of cancer registry data is of great importance to the usefulness of a cancer 
registry. To investigate the quality of its data the IKL cancer registry (Integraal Kanker-
centrum Limburg) performed a study with the aim of comparing data supplied by 
clinicians with data collected by registration personnel. 
Twenty clinicians reabstracted the information of a random sample of about ten of their 
patients, who were diagnosed with cancer in 1989 or 1990. After coding, the information 
was compared with the contents of the cancer registry records. For comparison of 
agreement the information of 190 cases was available. The relative frequency of major 
disagreements was 0% for date of birth, 0% for gender, 5% for date of incidence, 6% for 
primary site, 2% for laterality, 2% for histologic type and 2% for behaviour code. 
In general, the disagreements could be attributed to the handling of different coding 
rules (incidence date), or to a lower level of precision by the clinician in comparison to 
registration personnel (primary site). This study has shown that registration personnel 
are able to collect data with a degree of high accuracy. 
Introduction 
Cancer registries differ noticeably in the way data are collected. The Danish cancer 
registry receives the data on registration forms directly from general practitioners, 
practising specialists, hospital departments, etc. [1]. Other cancer registries in Great 
Britain and the United States collect data by specially trained registration personnel [2]. 
When the Netherlands cancer registry started in the early eighties, the regional cancer 
registries opted for active data collection by registration personnel. The willingness of 
clinicians to complete cancer registry forms was expected to be low. 
However, the accuracy of registration personnel in collecting the data was questioned 
by some clinicians. But the accuracy and the reliability of the data is of vital importance 
for the cancer registry, because it is generally accepted that the usefulness of a cancer 
registry depends largely on the quality of its data [3]. To investigate this quality the IKL 
cancer registry performed a study in 1991 with the aim of comparing data that are sup-
plied by clinicians with data collected by registration personnel. 
Methods 
The IKL cancer registry (IKL='lntegraal Kankercentrum Limburg' or 'Comprehensive 
Cancer Centre Limburg') was established in 1984 and is located in Maastricht. From 
1986 onwards, all nine hospitals and seven pathology laboratories in the Limburg region 
were participating in the registry. Recently, incidence data for the period 1986-1988 
have been published [4,5]. The cancer registry receives lists of newly diagnosed cases 
on a regular basis from the seven pathology departments in the region. In addition, lists 
of hospitalized cancer patients are obtained from the medical record departments of the 
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nine hospitals and the Radiotherapeutic Institute. Following this notification, the medical 
records of newly diagnosed patients (and tumours) are collected and the relevant 
information for the cancer registry is abstracted in the hospital from the medical records 
by trained registration personnel of the IKL cancer registry [4]. Topography and mor­
phology are coded according to ICD-Oncology [6]. Data that are entered into the 
database are extensively checked for possible errors, inconsistencies and duplicate 
records. 
Study design. Twenty-eight clinicians were chosen from the clinicians, that participate in 
the activities of the comprehensive cancer centre. Of them, twenty agreed to participate 
in the study Their distribution, according to specialism and hospital, was representative 
for the clinicians in the IKL area. From the cancer registry database of each clinician 
about ten patients diagnosed in 1989 or 1990 were selected at random. The clinician 
was asked to fill in a cancer registry form, that was developed especially for this study, 
for each of his patients. The form was accompanied by a comprehensive explanation. 
The collected items were date of birth, gender, date of incidence, primary site (to be 
completed in free text), laterality, histologic type (free text) and behaviour code (in free 
text). The returned forms were coded by one of the senior staff members of the cancer 
registry. The coded forms were returned to the clinician and only after approval the 
codes were compared with the original information in the cancer registry Differences 
were divided into minor and major disagreements according to an adapted proposal 
from a reabstracting study [7] and are summarized in Table 4.1. For histologic type the 
ICD-0 codes were merged into clinically and epidemiological^ relevant groups [8]. 
Table 4.1 : 
Definition of minor and major disagreements 
Item 
Date of birth 
Gender 
Date of 
incidence 
Primary site 
example 
Laterality 
example 
Histologic type 
example 
Behaviour code 
example 
Codes 
ICD-O 
ICD-0 
ICD-O 
Minor disagreement 
— 
-
< one month 
difference in the fourth digit 
different lobes of the lung 
other differences 
nghtvs unknown 
other differences in the first three 
digits 
carcinoma vs squam cell care 
— 
Major disagreement 
any difference 
any difference 
> one month 
difference in first three digits 
or difference in the fourth digit if 
154 0-1 vs 154 2-3 
lung vs larynx 
nght vs left 
difference in major groups3 
squam cell care vs adenocarc 
0-2 vs 3-9 
in situ vs invasive 
a) According to Berg [8] the histology was merged into ten groups, ι e epidermoid carcinoma, adeno­
carcinoma other specific carcinoma, unspecified carcinoma, lymphomas, sarcomas and other soft tissue 
tumours, other specified (and site-specific) types of cancer, unspecified types of cancer and leukaemias 
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Results 
The twenty clinicians completed 190 cancer registry forms. For one clinician only eight 
eligible patients (instead of ten) could be selected. Two of the clinicians returned only 
twelve out of twenty forms in time. All the coded information of the forms was approved 
by the clinicians. In Table 4.2 the results of the comparison of the clinicians' data with 
the original cancer registry data are presented. 
Table 4.2: 
Results of the comparison of the data supplied by clinicians with those by registration personnel 
Items 
Date of incidence 
Gender 
Date of incidence 
Pnmary site 
Laterality 
Histologic type 
Behaviour code 
Number 
of cases 
N 
190 
190 
190 
190 
105 
190 
190 
In exact 
agreement 
N 
190 
190 
102 
151 
92 
163 
187 
(%) 
(100) 
(100) 
(54) 
(79) 
(ΘΘ) 
(86) 
(98) 
Minor disagreement 
N 
a 
_ a 
78 
28 
11 
23 
(%) 
(-) 
H 
(41) 
(15) 
(10) 
(12) 
(-) 
Major disagreement 
N 
0 
0 
10 
11 
2 
4 
3 
(%) 
(0) 
(0) 
(5) 
(6) 
(2) 
(2) 
(2) 
a) For these items a minor disagreement was not defined 
Table 4.3: 
Major disagreements for primary site and histologic type 
Clinician 
ICD-O Description 
Topography 
143 9 
154 0 
153 3 
158 0 
199 9 
153 8 
162 9 
174 9 
194 0 
Gum, NOS 
Rectosigmoid junction 
Sigmoid 
Pentoneum, NOS 
Primary site unknown 
Colon, other 
Lung, NOS 
Breast, NOS 
Suprarenal gland 
Histologic type 
9593 
8230 
8030 
9823 
Large cell non-Hodgkin lymphoma 
Solid carcinoma 
Giant cell and spindle cell 
carcinoma 
Chron lymph leukaemia 
Cancer 
ICD-0 
145 9 
153 3 
154 0 
183 0 
183 0 
199 9 
199 9 
199 9 
199 9 
8070 
8240 
8830 
9671 
Registry 
Descnption 
Oral cavity, NOS 
Sigmoid 
Rectosigmoid junction 
Ovary 
Ovary 
Pnmary site unknown 
Primary site unknown 
Pnmary site unknown 
Pnmary site unknown 
Squamous cell carcinoma 
Carcinoid 
Leiomyosarcoma 
Immunocytoma 
Number 
of cases 
2 
2 
1 
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No disagreements were detected in date of birth and gender. With respect to date of 
incidence 10 cases (5%) contained major and 78 cases (41%) contained minor differ-
ences. The majority of these differences can be attributed to the use of other coding 
rules by the clinician. For example, the clinician often considers the date of first con-
sultation as date of incidence, whilst the cancer registry uses the date of first micro-
scopic confirmation. 
Comparison of the primary tumour site revealed 11 major (6%) and 28 minor (15%) 
disagreements between clinician and registration personnel (see Tables 4.2 and 4.3). 
The majority of the disagreements (9 out of 11) are related to the malignancies of the 
rectosigmoid junction or primary unknown site. With respect to the rectosigmoid junction 
it turned out that the clinician in two out of three cases agreed with the registry coding 
after reviewing the files. 
With respect to the item laterality two major differences were found. In one case the 
clinician had made a coding error, and in the other the case could not be verified. 
For histologic type only 4 major differences (2%) were detected. In Table 4.3 the major 
differences are listed. Three of the disagreements could be attributed to coding errors of 
registration personnel. The majority of the minor differences (15 from 23) was coded 
more specifically by the cancer registry (e.g. papillary adenocarcinoma opposed to 
adenocarcinoma). In five other minor differences the clinician used the more specific 
description of the histology). 
Three times (2%) there was a major disagreement in the behaviour code. Once registra-
tion personnel had incorrectly coded 'malignant' instead of 'borderline' (a refractory 
anemia with excess blasts was coded as leukaemia). Therefore, this tumour was 
wrongly included in the database, because borderline tumours should not be registered. 
In total, 161 cases (85%) were in agreement for all investigated items or had only minor 
disagreements; 28 cases (15%) had one major disagreement and 1 case (0.5%) had 
two major disagreements. 
In Table 4.4 the percentages of major disagreements for date of incidence, primary site 
and histologic type and the percentage of records with a major disagreement were 
shown according to groups of tumour sites. The percentages of major disagreements 
are the highest for lymphatic and haematological malignancies and malignancies with 
an unknown primary site. 
Discussion 
In 29 out of 190 cases (=15%) we found one or more major disagreement between the 
information recorded by the clinician and the cancer registry. Most disagreements were 
observed for the item primary site (N=11). Of these, five were coded by IKL as primary 
unknown. In only four out of the nine original cases did the clinician agree with the 
topographic diagnosis 'primary site unknown'. We suppose that the clinicians handled 
different rules for defining primary unknown malignancies. It is also possible that the 
primary site of the neoplasm had become clear some time after the abstracting and 
coding of a case by registration personnel (which happens 3-6 months after diagnosis). 
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The high frequency of disagreement with respect to the malignancies with primary 
unknown site is notable, also in view of the high incidence rates of this entity for males 
for the IKL cancer registry in comparison with other registries [9]. In contrast, the incid-
ence rates of this entity in females are comparable with other cancer registries [4]. 
Another frequent disagreement concerned the sigmoid colon and rectosigmoid junction. 
It is our experience that the different responsible clinicians often disagree over the same 
patient with respect to this topographical diagnosis in the reports. The differences in 
treatment and prognosis of sigmoid and rectosigmoid cancer are not substantial. For a 
clinician this difference in topography is therefore unimportant. 
For histologic type, the number of major disagreements was small. Two of the disagree-
ments would probably have been reported by computer software developed to trace 
inconsistencies. At the moment of the study, such a program had not yet been used for 
this part of the database. Although the percentage of major disagreements for beha-
viour code was low (2%), it will cause bias. The distinction between invasive and non-
invasive is often decisive for inclusion in incidence statistics, which are often limited to 
invasive malignancies only. The differences in this study concerned cases of a refract-
ory anemia (coded as leukaemia), invasive breast cancer (coded as non-invasive) and 
a non-infiltrating papillary bladder cancer (coded as invasive). The prevention of these 
errors asks for more attention in the training of the registration personnel. 
Recently, a comparable study of the quality of registry data has been published [10]. 
This study focused on disagreements in primary site. The number of major disagree-
ments (11 out of 200 cases) was quite similar to our study, despite the use of other 
criteria. They reported a considerable number of disagreement with respect to malig-
nant lymphomas. They attributed this to the fact that the lymphoma chapter of the ICD-9 
has become outdated. In our study the malignant lymphomas were not especially prone 
to disagreements with respect to histologic type. We ascribe this to the fact that the 
Netherlands Cancer Registry uses the ICD-0 and has developed special codes for the 
histology of malignant lymphomas [11]. 
The quality of cancer registry data has received increasing attention in recent years, but 
only relatively few studies on this issue have been published. Those studies are in 
general focused on 'completeness' or 'accuracy' [12]. The studies on accuracy are, in 
fact, reproducibility studies. In this study we compared data from the source (the 
clinicians) with the data as abstracted and coded by registration personnel. The data 
from the clinicians cannot be used as a golden standard, because clinicians and regis-
tration personnel collect data with a different perspective. Whereas clinicians use their 
data for making the decisions on treatment and prognosis, registration personnel are 
trained to accomplish uniformity with the help of strict coding rules. Some clinicians did 
supply information with less than required detail, because the more detailed information 
was not directly relevant for their daily clinical practice. Another possible reason for 
differences in information are differences in knowledge of the medical background of the 
patient. Registration personnel have to rely on the information in the clinical files, which 
is sometimes not fully complete. The clinician has more direct information on the patient 
and his disease, but has less knowledge of the coding rules of the cancer registry.ln 
general, the information supplied by clinicians does agree rather well with the informa-
tion abstracted and coded by registration personnel. 
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It can therefore be concluded that registration personnel, as trained and supported in 
the Netherlands cancer registries, are capable of collecting data for the cancer registry 
with a high degree of accuracy and reliability. However, coding rules for unknown 
primary malignancies ought to be improved and in some aspects the registration per­
sonnel need more training. 
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Introduction 
The IKL cancer registry in the Province of Limburg was established in 1984 as part of 
the Comprehensive Cancer Centre Limburg (Integraal Kankercentrum Limburg: IKL). 
Within the structure of the centre, the hospitals, the university of Limburg and the 
radiotherapeutic institute of Limburg are collaborating. The aim of the centre is the 
improvement of the care for cancer patients. Besides cancer registration, the centre is 
involved in cancer research and treatment and coordinates regional activities on cancer 
prevention, screening, education and psychosocial care. The cancer registry provides 
important information on which several of these activities are based. 
The IKL cancer registry Is one of the nine regional cancer registries in The Netherlands. 
Together, these registries will comprise a nation-wide cancer registry in the Nether-
lands. After the IKL cancer registry started in 1984, it has gradually expanded in the 
following years. From 1986 onwards, all hospitals and pathology laboratories in the 
region have been participating in the registry. The registry publishes annual reports with 
respect to the registered malignancies [1-3]. Incidence rates have been published 
recently [4-6]. For this publication data for the period 1986-88 are used. 
Methods of Cancer Registration 
The cancer registry receives lists of newly diagnosed cases on a regular basis from the 
seven pathology departments in the region. In addition, lists of hospitalized cancer 
patients are obtained from the medical records departments of the nine hospitals. 
Following this notification, the medical records of newly diagnosed patients (and 
tumours) are collected and the relevant information for the cancer registry is abstracted 
from the medical records by trained tumour registrars. 
Tumour data are coded according to ICD-O. Completeness of records, data consistency 
and the possibility of duplicate records are continuously and extensively checked by 
computer programs. Due to privacy regulations death certificates cannot be used as an 
additional source of notification of cancer cases in The Netherlands. 
Area covered by registry and population data 
The area of the IKL cancer registry consists of the southern and middle part of the 
province of Limburg, which is situated in the south-east of the Netherlands (Fig. 1). 
The area of the IKL cancer registry comprises about 1355 km2 and it includes rural, 
urban and rather heavily industrialized areas. Population data are provided on an 
annual basis by the Central Bureau of Statistics. On 1 January 1987 the population at 
risk consisted of 835 727 inhabitants, of which 414 558 were men and 421 169 were 
women. In the southern part of Limburg the population density was 927/km2, whereas in 
the middle part this was 319/km2. About 26% of the population lived in rural, 49% in 
suburbanized and 25% in urban municipalities. 
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Figure 5.1 : Area of the IKL cancer registry ¡η the 
Netherlands 
Current industrial activities in the region include chemical, automobile and cement 
industry. From 1910 until 1975 coal mining was a very important source of employment 
in the region; the province of Limburg has been the only mining region in the Nether­
lands. 
Results 
From 1986 to 1988 a total of 8409 new malignancies were recorded in the IKL cancer 
registry (4550 in males and 3859 in females), non-melanoma skin cancer and non­
infiltrating malignancies excluded. Of these tumours, 2798 were diagnosed in 1986, 
2743 in 1987 and 2868 in 1988. 
Of all these malignancies 88.4% had been histologically, 6.7% cytologically and 4.9% 
only clinically verified. 
In Figure 5.2, age-adjusted rates per 100 000 inhabitants (standardised according to the 
world standard population) are presented. 
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Figure 5.2: Age-adjusted incidence rates (standardised according to the world standard population) per 
100 000 for major cancer sites in males and females (IKL cancer registry, the Netherlands, 1986-88) 
Number of registered cases is given in parenthesis. 
In males, lung cancer is the most common cancer site with an annual incidence rate of 
83.5 per 100 000 (world standard population), followed by cancer of the prostate (29.7), 
colon (19.8), stomach (16.8), rectum (16.4) and urinary bladder (11.1). In females, 
breast cancer is the most common malignancy with an incidence rate of 68.4 per 
100 000, followed by cancer of the colon (17.2), corpus uteri (10.6), rectum (10.3), lung 
(9.2) and ovary (9.0). 
The world standardised rate for total cancer was 274.0 In males and 195.7 in females. 
Mortality data of the IKL-area for the years 1986-88 were obtained from the mortality 
register of the Central Bureau of Statistics. In Figure 5.3, the mortality : incidence ratios 
are presented for the most frequent malignancies. The mortality : incidence ratio for 
total cancer is 0.77 in males and 0.63 in females. Of the most frequent cancers only the 
mortality : incidence ratio for lung cancer in females is slightly higher than 1. 
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Figure 5.3: Mortality : incidence ratio for common cancer sites (Incidence: IKL cancer registry, 19Θ6-ΘΘ; 
Mortality: Central Bureau of Statistics 1986-88) 
Discussion 
In this article incidence rates are presented from a cancer registry in the Netherlands 
that has been established only recently. Despite the relatively short time that has 
elapsed since the start, we have reason to believe that our registry is already rather 
complete. Notifications have been obtained on a regular basis from pathology laborat­
ories and hospitals for several years. From 1986 onwards, all pathology laboratories 
and hospitals participate in the cancer registry, resulting in a number of registered 
cases, which is rather constant for 1986,1987 and 1988. The mortality : incidence ratio 
for total cancer in men and women and the fact that of the most frequent sites only the 
ratio for female lung cancer exceeds 1, indicate no substantial under reporting of cancer 
incidence. Finally, the completeness of the registration has been tested in a pilot study 
in which the registry data were compared against data on cancer patients in a com­
puterized network of general practitioners in the area. Preliminary results suggest a 
completeness of 95% [7]. 
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Overall, the incidence rates of the IKL cancer registry are very closely corresponding to 
the rates of the Eindhoven Cancer Registry in The Netherlands for the years 1983-86 
[5,8-9]. The latter registry has been in operation since 1975 and is presumably complete 
[10]. However, the incidence rates are lower in the IKL-area than those in the Eind-
hoven cancer registry for malignancies of the stomach (males and females), bladder 
(M,F) and ovary. The incidence rates are higher for malignancies of the lung (F), pleura 
(M) and primary site unknown (M). The general correspondence between the incidence 
rates is in accordance with the similarity of cancer mortality rates in both regions [5]. 
While the differences for most cancer sites are modest, the difference between the 
incidence rates of bladder cancer is striking. This however, can be attributed to dif-
ferences in coding practices. In the IKL cancer registry non-infiltrating papillary bladder 
cancers are not coded as infiltrating, as opposed to the past practice in the Eindhoven 
cancer registry. If the non-infiltrating papillary bladder cancers would be regarded as 
infiltrating there would be no difference in incidence rates for bladder cancer between 
the two regions [5]. In comparison with the remaining parts of The Netherlands, cancer 
mortality in males is 5% higher in the areas of the Eindhoven and IKL cancer registries, 
while for females there is no difference [5,9]. The lung cancer incidence rate in men in 
the IKL cancer registry is high in comparison with other European cancer registries. 
Only the cancer registries in the United Kingdom and the cancer registry of Eindhoven 
have reported comparable rates [11-12]. The incidence rate of lung cancer in females is 
rather low, which can be explained by the fact that cigarettes smoking was not common 
among females in the Netherlands before 1970. Because of the increasing number of 
women that smoked cigarettes from 1970 onwards, it can be expected that the incid-
ence of lung cancer in women will rise [13]. 
The incidence rate of pleura mesothelioma is rather high in the IKL area in comparison 
to the other cancer registries in Europe [11]. This might be due to the exposure of as-
bestos, which has been widely used as Insulation in the chemical industry, one of the 
biggest employers in the region. The incidence of colorectal malignancies, breast and 
kidney cancer are high. These malignancies can mostly be attributed to lifestyle factors 
and further studies are indicated to explain these differences. 
In a recent publication the cancer incidence in the countries of the European Commun-
ity has been estimated [14]. The incidence rates were calculated using the mortality : 
incidence ratio of cancer registries in the Nordic countries, Scotland and some French 
regions. The estimated incidence rate for total cancer for the Netherlands is about 10% 
higher than the recorded incidence rate for the IKL cancer registry. When non-infiltrating 
bladder cancer was included, the estimated number of all malignancies was 5% higher 
in males and 9% higher in females. These figures are comparable to the results of the 
Eindhoven cancer registry. In Scotland the estimated number of cases was 5.2% and 
7.9% higher, for males and females respectively, than the actually observed number 
[14]. It is therefore possible that the expected number of incident malignant tumours is 
overestimated by Jensen era/, for The Netherlands. This can be investigated when the 
data of the national Dutch cancer registry are available. In this publication, incidence 
rates were presented of a recently established cancer registry in the Netherlands. They 
provide further insight in the pattern of cancer incidence in Europe. 
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Apartfrom the estimation of cancer incidence, the registry is involved in etiologic cancer 
research [15-16]. In the IKL cancer registry a protocol was developed for the record 
linkage between the Dutch cancer registry and cohort studies [17]. 
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Abstract 
Background: Differences in cancer incidence have been observed between urban and 
rural communities for many decades. These differences have been attributed for the 
most part to lifestyle aspects. In Western populations, however, differences in lifestyle 
have diminished. This study addressed the question: For which cancer sites can differ-
ences in cancer occurrence still be demonstrated between urban and rural communities 
in the Netherlands? 
Methods: Cancer incidence data from 1989 to 1991 inclusive, were obtained from the 
Netherlands Cancer Registry. Age adjusted, site-specific incidence rates were calcu-
lated for five classes of municipalities classified by address density. 
Results: With increasing urbanization, slightly higher incidence rates were observed for 
all cancer sites combined (rate ratio [RR]= 1.08 in males and 1.12 in females). Statist-
ically significant RR of > than 1.4 were observed for Kaposi's sarcoma (m), 
mesothelioma (m), cancer of the liver (m), mouth/pharynx (m+f), oesophagus (f), larynx 
(f), lung (f), other respiratory organs (f), cervix (f) and Hodgkin's disease (m). Signific-
antly lower incidence rates were found in urban areas for non-melanoma skin (m+f) and 
lip cancer (m). 
Conclusions: In males, the urban excess of tobacco-related cancer has largely dis-
appeared. However, urban-rural differences in cancer incidence still exist for other 
cancer sites and for tobacco-related cancer in females. Apparently, differences in the 
prevalence of lifestyle factors are still large enough to cause variation in cancer incid-
ence. 
Introduction 
Differences in cancer incidence have been observed between urban and rural commun-
ities for many decades [1-7]. In general, the risk of cancer is higher in urban popu-
lations. However, these differences seem to have diminished over the past few years, 
especially in industrialized countries [7]. 
As in most other populations, urban-rural differences in cancer mortality and incidence 
were also reported in the Netherlands [8-9]. Hoogendoorn found higher mortality rates 
for cancer of all sites (males) and cancer of the lung, bladder and uterine cervix in the 
large cities than in the total Dutch population. In the province of Limburg, higher incid-
ence rates were found for cancer of all sites and cancer of the respiratory tract in urban 
communities [9]. The power of the latter study was too small to detect any differences in 
cancer incidence for other sites. 
The Netherlands is a small and densely populated country. Access to health care is 
excellent, both in urban and rural areas. Lifestyle differences between urban and rural 
areas are very small. 
In view of these aspects, it is doubtful whether there are still any urban-rural differences 
in cancer incidence in the Netherlands. An exception may be Kaposi's sarcoma, a 
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tumour associated with the epidemic of the Acquired Immuno Deficiency Syndrome 
(AIDS), because this epidemic is concentrated in the larger cities [10]. 
This study was performed to investigate whether there are still any differences in cancer 
occurrence in the Netherlands between urban and rural areas. 
Materials and methods 
Cancer incidence data from 1989 to 1991 were obtained from the nationwide popu-
lation-based Netherlands Cancer Registry by 5-year age group, gender and municipality 
[11-12]. Malignancies were classified according to the International Classification of 
Diseases for Oncology, version I (ICD-O) [13]. For the years 1988-1990, it was estim-
ated that the cancer registry was only 3.8% incomplete [14]. The Netherlands Cancer 
Registry does not record basal cell carcinoma of the skin. 
Information about population figures by 5-year age group, gender and municipality for 
January 1 1989,1990 and 1991 were obtained from the Dutch Central Bureau of Statis-
tics (CBS) [15]. The CBS has classified the municipalities by level of urbanization 
according to an index based on the address density of the surroundings [16]. Address 
density is defined as the number of addresses within a radius of 1 kilometre of an 
average address in the area. For each municipality the average address density was 
calculated for an 'average' address. Using this index, municipalities were classified into 
five groups: very dense urbanization (class 5), dense urbanization (4), moderate urban-
ization (3), sparse urbanization (2) and no urbanization (1) (Table 6.1). 
To study cancer incidence in relation to urbanization, analyses were performed for both 
sexes. Incidence rates in the five urbanization groups were age adjusted, using direct 
standardization to the European Standard Population [17]. This standard was chosen 
because it approximates the age distribution of the population of the Netherlands far 
better than the World Standard Population. Rate ratios (RR) were calculated by dividing 
the incidence rates of urbanization groups 2, 3, 4 and 5 by the rate of group 1. Age-
specific RR were inspected, because heterogeneity can cause bias in the interpretation 
of age-standardized RR. Age appeared not to be an effect modifier. The 95% confid-
ence intervals (95% CI) of the RR were calculated using the method described by 
Miettinen [18]. The slope of linear trends of age-standardized cancer incidence rates 
according to the level of urbanization were determined using the method described by 
Rothman [19]. 
Results 
The RR for densely urbanized versus rural municipalities for cancer of all sites and for 
30 separate cancer sites in males and 31 sites in females are presented in Figures 6.1 
and 6.2. Rate ratios and an estimate of the linear trend with 95% CI for all the urbaniz-
ation groups compared to the rural municipalities are presented in the Appendix. 
52 Chapter 6 
.+ ..· 
"
+ + ψ } } + + + + Η ι 
'
+ + +
н 4 | + 
I I I I I I L_l I I ' 
¡||I 
ё
 r, 
Я О 
В S 
° 2 
Q. 
' ' ' ' ' ' ι ' ' ' ι ' ι ' ' ι ι ι ι 
5 Q . Q . и Î T I a. XZ £ M . »· 8 - i: ^ 3 > JE 
£ s £ с § a ξ ΐ μ ^ ε » 8 f; 3 
О œ E с - Ь > . ï ™ = « < Φ ·= o _j 
' ' i ' 
3 
о 
(Л С Л Q. 
2 5 E 3 
» S ì 
8 
ç 
JÉ 
СО 
S 
5 S 
£ -8 £ 
C
 >> ш ili 
о co Ç 
о > 
(О 
чР с я 
о ^ — со 
S g S 
•о I "g 
ce 5 S 
S о « 
2 ев £ я 
« с S ε 
« я §•* 
Œ
 " о о 
" і — я і -
со -—- я го 
o g r o 
w я та · 
{ 
+ + 
+ H+f + + + ---• + * + + + - + - + * 
• + + 
+ 
' ι ι ι I ι ι ι ι ι I I I I I I I I 
со л E E 
9 S 
£·•& 
ΙΛ C D C £ 
ΰ ι- ^ U 
" S í ? 
- ra 2 £ 
E ' S m О 
СО 
e g o 
S о 
E 3 
2 ε 
5 
о 
2 
3 ¿ i 
Я 
о 
га 
-
о 
^ 
г 
¡3 t 
si 
со 
lU 
г* 
CD 
Ç 
CD 
υ CD 
• a 
с 
о ü 
~-S 
0 ) 
•о 
с 
η 
со 
о 
'S 
5 
a (Г 
^ 
<Т1 
η 
3 
>< 
CD 
CO 
С 
CD 
• σ 
&· CD 
> 
С 
CD 
С) 
С 
л 
υ 
CD 
υ 
с 
S 
Г) 
,—^  
« О I* 0) in 
Ш 2· 
СО 
тз 
с 
я 
•с φ £ 
Φ 
Ζ 
φ 
JZ 
я 2 
я 
я 
¿ 
2 
¡υ CD 
Я я 
ЕЕ 
8 £ 
СО τ­
η ГО 
CD ГО 
Я Τ 
-г, ГО 
^ со 
Φ 3) 
Urbanization and cancer incidence 53 
Table 6.1: 
Population and average population density on January 1, 1990 and the number of newly registered cancer 
cases from 1989 to 1991, by address density in the Netherlands 
Class 
1 
2 
3 
4 
5 
Urbanization of municipalities 
Non-urban (<500 addresses/km2) 
Sparse (500-<1000 addresses/km2) 
Moderate (1000-<1500 adresses/km2) 
Dense (1500-<2500 adresses/km2) 
Very dense (>2500 adresses/km2) 
Total 
No of inhabitants 
Males 
N 
1 564 549 
1 541 670 
1 448 743 
1 497 216 
1 305 107 
7 357 285 
Females 
N 
1 532 604 
1 548 091 
1 499 048 
1 565114 
1 388 796 
7 533 653 
Population 
density 
N/km2 
164 
349 
810 
1721 
3807 
439 
No of cancer cases 
Males 
N 
18 607 
17 561 
17 243 
18 724 
18 788 
90 923 
Females 
N 
14 775 
15 217 
15 907 
17 234 
17 954 
81 087 
In males and females, slightly higher incidence rates were found for urban versus rural 
areas for cancer of all sites. In males, the RR was 1.08 (95% CI: 1.06-1.10) and in 
females, the RR was 1.12 (95% CI: 1.09-1.14). In both males and females a statistically 
significant increasing trend of standardized incidence rates [19] was observed with 
group of urbanization for cancer of all sites. 
An extremely large urban excess was observed for Kaposi's sarcoma (males: 
RR=15 97), mesothelioma (гтг RR=3 27), malignancies of the liver and intrahepatic bile 
ducts (m: RR=2.54) and cancer of the lung and bronchus (females RR=2.13). 
A large urban excess (RR > 1.4) was observed for the larynx (f. RR=1.91), the nasal 
cavity and other respiratory organs (f: RR=1.83), the cervix (f: RR=1.69), the mouth and 
pharynx (m RR=1 64; f- RR=1.45), the oesophagus (f: RR=1 46) and for Hodgkm's 
disease (m: RR=1.43) These observations were supported by statistically significant 
linear trends in incidence rates, except for cancer of the nasal cavity in females. A 
smaller but significant urban excess was observed for seven and six other cancer sites 
in males and females, respectively The finding of a higher risk in urban municipalities 
was supported by an increasing trend with urbanization for most of these sites (Ap­
pendix). Statistically significant lower RR were found in very densely urbanized versus 
rural areas for non-melanoma skin cancer (m: RR=0.68, f: RR=0.74) and lip 
(m: RR=0 37). These findings were supported by a decreasing linear trend in cancer 
incidence rates with urbanization (Appendix). 
Discussion 
In general, the cancer nsk in the Netherlands is higher in urban areas and the risk 
increases with the level of urbanization A statistically significant increasing linear trend 
of age-standardized incidence rates was demonstrated with increasing address density 
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for 15 out of the 30 sites in males and for 13 out of the 32 sites in females. For cancer of 
the lip (males) and non-melanoma skin cancer (males and females), a rural excess was 
found and the incidence rates decreased with increasing urbanization. 
The results of this study are in agreement with those of most other reports in the liter-
ature [2-7,9]. Extreme urban excesses have been reported for cancer of the lung, liver, 
larynx, mouth and pharynx, bladder and oesophagus; moderate urban excesses have 
been reported for cancer of the colon, rectum, cervix uteri, kidney, breast, ovary, brain 
and pancreas, while slight urban excesses have been reported for Hodgkin's disease, 
cancer of the testis, stomach, melanoma, other skin, corpus uteri, prostate, leukaemia 
and non-Hodgkin lymphoma [7]. Two types of cancer have been reported to occur at 
higher rates in rural areas, i.e. lip cancer and eye melanoma [7]. The most likely ex-
planations for the differences in cancer incidence between urban and rural areas are 
aetiological factors, such as the inhabitants' personal behaviour, air pollution and 
occupational hazards. Examples of personal behaviour are cigarette smoking, alcohol 
consumption, sexual promiscuity, exposure to ultra-violet radiation, diet and family size 
[7]. 
Cancer of the lip and non-melanoma skin cancer are thought to be caused primarily by 
exposure to ultraviolet radiation [20-22]. People in rural areas are more likely to be 
exposed to ultraviolet radiation because of outdoor work. The higher incidence of lip 
cancer in rural areas is in agreement with other studies [7], but the excess in the incid-
ence of non-melanoma skin cancer is not. The higher incidence of eye malignancies in 
rural areas could not be confirmed in this study. 
In general, the incidence rates of tobacco-related cancer [21], such as cancer of the 
lung, larynx, mouth and pharynx, oesophagus, pancreas, cervix, urinary bladder, renal 
pelvis and kidney, are higher in urban areas. However, in this study the urban excess 
was only observed in females. In two earlier studies in the Netherlands, an urban 
excess was found for cancer of the respiratory tract in females and males [8-9]. In the 
southeast of the Netherlands, lung cancer incidence rates in males were higher in urban 
areas until 1975; in females, the lung cancer incidence rates have continued to rise in 
urban areas [23]. The difference between the sexes in the current study and the findings 
in the other studies reflect the pattern of smoking habits in the Netherlands [24]. 
In 1963, 82% of all Dutch males were smokers. From the 1970s onwards, smoking 
prevalence in males decreased to 38% in 1993 [25]. In 1963, only 32% of all Dutch 
females smoked. But, in contrast to the trend in males, smoking prevalence in females 
increased in the 1970s, especially in the urban population [26]. 
A large urban excess was observed for malignant mesothelioma in males. This malig-
nancy is usually located in the pleura and sometimes in the peritoneum. Asbestos is 
known to be the main risk factor for pleural mesothelioma [21]. Many shipyards are 
located in the two largest Dutch cities, Rotterdam and Amsterdam, and shipyard 
workers have been exposed to asbestos in the past. 
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It is difficult to interpret the results for cancer of the prostate and breast. In the Nether-
lands, screening programmes for these types of cancer have been started fairly recent-
ly, which makes it difficult to unravel the effects of screening and the degree of urbaniz-
ation. Besides a screening effect, an explanation for the urban-rural differences in 
breast cancer incidence can possibly be found in parity. In the past decades the rate of 
live births in the larger cities has remained lower than that in the rest of the Netherlands 
[27]. 
A large urban excess was observed for cervical cancer. Recently, a screening 
programme started for this type of cancer. Main causes for cervix cancer are considered 
to be sexual promiscuity, smoking habits and the human papillomavirus. The incidence 
of the other malignancies that are related to viruses, Kaposi's sarcoma and malig-
nancies of the liver, are also increased in urban areas. Kaposi's sarcoma is associated 
with the AIDS epidemic. Because of a deficient immune system, people with AIDS are 
at increased risk for developing Kaposi's sarcoma. As in other countries, the AIDS 
epidemic in the Netherlands has settled down in the larger cities, especially in Amster-
dam. Liver cancer is very rare in the native Dutch population. However, the incidence 
rates of liver cancer are higher in sub-Saharan Africa, East and Southeast Asia and in 
Melanesia [21,28]. The Netherlands has a relatively large group of immigrants from the 
former Dutch colonies (Indonesia, Surinam and the Netherlands Antilles) and from 
many other countries (especially Morocco and Turkey, but recently also from Ghana, 
Somalia and Cape Verde). Immigrants tend to concentrate in the larger cities in the 
Western part of the country [29]. The urban excess of liver cancer in this study may 
purely reflect the distribution of these peoples. 
In this study address density was used to estimate urbanization. Address density is 
strongly correlated with population density. The average population density of the very 
dense urbanized municipalities was in the same range as the highest urbanization 
classes of the studies conducted in New York and Illinois [4,6]. However, the average 
population density of the non-urban municipalities was higher than the rural commun-
ities in the American studies. The contrast in population density in our study was there-
fore smaller. 
In addition to aetiological factors, bias may also cause the urban-rural variations in risk. 
Bias can occur due to incompleteness of case ascertainment, errors in case registration 
and inaccurate residential information. In theory, underdiagnosis or incomplete records 
of cancer in the rural areas can be a reason for the differences. However, this is unlikely 
in the Netherlands in view of the good registration systems, both for cancer and place of 
residence as well as the nearly perfect health care infrastructure. 
Cancer latency periods and the migration of patients to other areas is another potential 
source of bias in ecological studies like this one. It is difficult to determine what the 
effect is of migration, but it is thought to be small. Annually, 4% of the Dutch population 
move from one municipality to another [15]; the new municipality may have the same 
class of urbanization. Moreover, cancer risks are highest in the elderly, whereas most 
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migration takes place in the younger population (less than 2% of the population of 40 
years and older move annually) [30]. 
In males, the urban excess of tobacco-related cancer has largely disappeared, while in 
females, the opposite is true for the occurrence of these types of cancer. Also, differ­
ences in cancer incidence have been observed for several other cancer sites. Therefore 
it is likely that differences in cancer incidence still exist in the Netherlands between 
urban and rural areas and that these differences can be attributed to a variety of lifestyle 
factors. 
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CANCER INCIDENCE: LIFE TABLE RISK VERSUS 
CUMULATIVE RISK 
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Abstract 
Study objective: To study differences between various methods of estimating cancer 
risk in individuals. 
Design: Information was obtained from a cancer registry. Lifetime risk was calculated 
using the life table method, taking competing causes of death into account and using 
well recognised methods such as the cumulative rate and risk. 
Setting: Regional cancer registry of the Comprehensive Cancer Centre IKL, located in 
Maastricht, The Netherlands. 
Patients: Patients with a first primary malignancy in 1989-1990 in the catchment area of 
the cancer registry. 
Main results: The lifetime risk of developing cancer was estimated to be 34.8% for 
males and 30.4% for females. In males, especially, the risk estimates were considerably 
higher when the cumulative risk was used. 
Conclusions: The life table method is convenient for estimating the probability that a 
person will develop cancer during a defined period or during his or her lifetime. The 
other estimates overestimate the risk of the disease under investigation, especially in 
the very elderly. 
Introduction 
When the first annual report of the Netherlands Cancer Registry [1] was published in 
1992, media attention was focussed on the estimates of the risk of developing cancer. 
Many newspapers stated that one in every three men and one in every four women 
would have cancer before the age of 75 years. These estimates were based on calcu­
lations of the cumulative risk [2]. In essence, cumulative risk is a conditional probability. 
Because it is conditional on survival until a certain given age, it will overestimate the risk 
of developing cancer at an advanced age, when there is a greater risk of dying from a 
competing cause. It is possible to adjust for the effect of competing causes of death, by 
using life expectancy tables. This method was first descibed in the 1950s [3-4], but has 
received widespread attention only recently [5-6]. 
We applied the life table method and the traditional cumulative risk method to the 
cancer incidence data from a regional cancer registry in The Netherlands to study the 
differences in risk outcomes. 
Methods 
Cumulative risk and cumulative rate versus life table risk 
In the reports of cancer registries, first occurrences of cancer in a given geographical 
area and in a defined period of time are usually organized into gender and five year age 
groups. The age groups are 0-4, 5-9 80-84, 85+. The total number of incident 
cancers in age group χ is denoted by c„ x=1,2,...,18. Let nx denote the number of 
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person-years of age group x. The cumulative risk P
№
 until the age of 85 years is defined 
as [2]: 
Pcn^-exp(-5^—) (1.1) 
x-1 П
х 
The cumulative rate P^ until the age of 85 years is defined as [2]: 
Раш-^Σ^. (1.2) 
The cumulative rate approximates the cumulative risk for low risk values less than 
approximately 10%. Both expressions are conditional upon survival. Neither the cumu­
lative rate nor the cumulative risk take competing causes of death in the population into 
account. A more realistic estimate of the cancer risk can be made if life expectancy 
tables are available for the study population. In this case a hypothetical cohort of 
100 000 individuals is defined at age 0. Subsequently, the number of person years, 
denoted by y„ can be calculated in each five year age group of the hypothetical cohort. 
The total number of individuals who will develop cancer in this hypothetical cohort, C
№
 in 
a particular life period is given by: 
c„ = E — (1.3) 
x-1 nx 
The lifetime risk of developing cancer is then given by: CK /100 000. The risk Рй(0ч) of 
developing cancer from birth until the end of age group / is: 
P f f ( M = ( Σ — )/ 100 000 (1.4) 
x-1 П
х 
In this article we refer to this method in the expression of life table cancer risk. 
The risk of developing cancer before the age of 80 years for an individual who is alive 
and free from cancer at age 40 years is: 
ρ*(4ο-8θ) = ( Σ ^ ) / / ; ο o-s) 
x-9 П
х 
where /'^ is the total number of cancer free individuals at the age of 40 years. This 
number of cancer free individuals at age χ can be estimated if the number of cancer 
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deaths in all the age groups of the population under study are available. For details, see 
Zdeb [7]. 
Calculation of variance of the cancer risk 
The variance in the total number of individuals who develop cancer from birth until the 
end of age category / is given by: 
VAR [C„(0J = VAR Σ i — I = Σ У* VAR [ 2l ] 
x-1 П x-1 Π 
(2.1) 
Assuming cancer incidence has a Poisson distribution, the variance of cx/nx is given by: 
(2.2) VAR[fl]=fl 
n. 
Therefore: 
n, 
VAR[CII{0.]=Y; к y;
c
* (2.3) 
x-1 П
х 
The 95% confidence interval for С
й(0ч) is given by: 
C » ( M ± 1 . 9 6 
N 
«Ц Г,с
я 
(2.4) 
Jf-1 n„ 
Dividing the lower and upper limits of the confidence interval for С
Н(о_0 by the total 
number of individuals at birth (100 000), gives the confidence interval for the risk PKVH) 
of developing cancer from birth to the end of age category /. 
The variance in the cumulative rate based on the Poisson distribution is given by [2]: 
VAR [ Pcm ] = 52 £ Í ( л / 
The 95% confidence interval for Pcra is given by: 
(2-5) 
P O T ± 1 . 9 6 ( 5 
N Jt-1 K)2 
(2.6) 
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and for Pcn the 95% confidence interval is given by: 
1 - exp ( -5 ( Σ— ± 1.96 
x-1 П
х N 
)) (2.7) 
Interested readers can obtain a computer programme for SAS from the first author to 
calculate the life table risk. 
Incidence and mortality data 
Incidence rates were obtained from the regional cancer registry IKL (=lntegraal Kanker­
centrum Limburg (Comprehensive Cancer Centre Limburg)), located in Maastricht [8-9]. 
All malignancies, including non-infiltrating malignancies, were recorded, with the excep­
tion of basal cell carcinoma of the skin and non-infiltrating cervical cancer. 
Completeness of case ascertainment was studied by comparison with an independent 
registry by general practitioners [10]. From this study the completeness of cancer regis­
tration was estimated to be at least 96%. 
Incidence rates in the years 1989 and 1990 were used in this study. For total cancer 
incidence, only the first recorded primary invasive malignancy was considered in the 
case of multiple primaries. For the incidence at specific sites, only the first recorded 
invasive malignancy at a specific site (according to the 9th revision of the International 
Classification of Diseases (ICD-9)) was used for calculating the incidence rates. For 
example, after a woman has developed cancer of the breast, the diagnosis of cancer in 
the contralateral breast was disregarded, but she remained eligible to develop cancer at 
a different site. 
Population and mortality data (both in one year age groups) and cancer mortality data 
(in five year age groups) from 1989-1990 for the catchment area of the IKL cancer 
registry were obtained from the Dutch Central Bureau of Statistics. A life expectancy 
table was constructed using the population and mortality data (summarised in Table 
7.1). 
Table 7.1: 
Summary of the life expectancy table for the IKL area in the period 1989-1990 
At age (y) 
0 
25 
50 
75 
Life 
expectancy (y) 
72.77 
49.04 
25.43 
7.38 
Males 
Persons 
alive 
100 000 
98 054 
94 081 
52 156 
Person years 
2 468 076 
2 416 040 
2 007 626 
385 163 
Life 
expectancy (y) 
79.52 
55.38 
31.37 
10.68 
Females 
Persons 
alive 
100 000 
98 842 
96 360 
74 024 
Person years 
2 478 653 
2 450 766 
2 231 849 
790 826 
Based on specific population and mortality data obtained from the Central Bureau of Statistics 
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Results 
For males, the life expectancy at birth in the period 1989-1990 in the area of the IKL 
cancer registry was 72.8 years. The life expectancy for females is 79.5 years, (see also 
Table 7.1). The annual age adjusted incidence rate per 100 000 person years (accord-
ing to the European Standard Population [11]) was 392.6 for males and 273.3 for 
females (first primary malignancies only). In Figure 7.1 age-specific incidence rates 
according to gender are presented. 
N/100 000 person years 
3,000 
2,500 
2,000 
1,500 
1,000 
500 
0 
-
- · -
- * > • • * - - * -
00- 05- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 60- 65+ 
Age 
Figure 7.1: Age specific cancer incidence rates according to gender. 
Only first primary malignancies are included, whereas basal cell carci-
nomas of the skin are excluded (IKL cancer registry, 1989-1990) 
Table 7.2 shows the cumulative cancer risk and the life table cancer risk for all malig-
nancies and for a number of common cancer sites. Using the cumulative risk, the risk of 
males developing cancer up to the age of 85 years was estimated to be 45.1%. The 
cumulative risk of females was estimated to be 30.4%. The life table cancer risk until 
this age was estimated to be 33.3% for males and 27.8% for females. 
The cumulative risk estimate was much higher than the estimate derived from the life 
table risk. In addition, the risk estimates of two common cancers in males were higher 
using the cumulative risk. In females, the differences between the cumulative risk and 
the life table method were smaller. 
The lifetime risk of developing cancer (the probability that an individual will develop 
cancer during his or her lifetime according to the life table method) was estimated to be 
34.8% for males and 30.4% for females. These percentages represent the average risk 
at birth that a member of the cohort will develop cancer during his or her lifetime. 
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The cumulative rate, cumulative risk, and life table risk of developing cancer for males 
and females are shown in Figure 7.2. In males, the cumulative risk deviates increasingly 
from the life table cancer risk from the age of 65 years onwards. In females, the various 
risk estimates do not differ significantly until the age of 85 years. 
Males Females 
Cum. rate 
•Δ- S0% 
Cum risk 
·€> 
Lile table risk 
-40 -45 -50 -55 -60 -65 -70 -75 -B0 -85 -90 
Age 
-40 -45 -50 -55 -60 -65 -70 -75 -SO -85 -90 
Age 
Figure 7.2: Cumulative rate, cumulative risk and life table risk of cancer in percentages from birth to a 
certain age for all malignancies in males and females (IKL cancer registry, 1989-1990) 
In Figure 7.3, the probability of eventually developing cancer from a given age onwards 
(for persons free of cancer at the beginning of the given interval) is shown for males and 
females. In males, after a slight increase, the probability remains stable until the age of 
50 years. Beyond this age the probability of developing cancer declines rapidly. In 
females, the probability is constant until the age of 40 years. Thereafter the decline in 
probability is less rapid than for males. Figure 7.4 shows the probability of developing 
prostatic cancer in males and breast cancer in females. The difference is striking. The 
probability of developing prostate cancer rises from 5.5% at birth to 6.1% at the age of 
60 years, but declines sharply thereafter. In contrast, the risk of developing breast 
cancer starts to decline from the age of 30 years onwards. The risk of developing breast 
cancer from birth is estimated to be 8.4%. 
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Life table risk 
40% 
35% 
30% 
25% 
20% 
15% 
10% 
5% 
.Or - O- - Θ- - G - -О • -©· · - - - О, - л 
•о. 
Female ' Ό · . 
О 
J I I Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι L 
0- 5 - 1 0 - 1 5 - 2 0 - 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85- 90-
Age 
Figure 7.3: Probability (%) of developing cancer in the remaining lifetime by 
age and sex for persons alive and free from cancer (IKL cancer registry, 
1989-1990) 
Life table risk 
10% 
2% 
0% 
Breast cancer 
©. - ·©-- G- - О - О --©—©—©.. ^ 
Q 
ι ι ι ι ι ι ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι Ι L 
0- 5- 10-15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- Β0- 85- 90-
Age 
Figure 7.4: Probability (%) of developing prostate cancer (males) and breast 
cancer (females) in the remaining lifetime by age for persons alive and free 
from these types of cancer (IKL cancer registry, 1989-1990) 
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Discussion 
More realistic cancer risk estimates were obtained using the life table method. There 
were large discrepancies with the other available methods -that is, cumulative rate and 
cumulative risk for the elderly- especially in males. The life table method produced a 
lower estimate because it is not conditional upon survival to an advanced age. 
There was less difference between the various estimates for women because at all 
ages the mortality rates for women are lower than those for men. As a consequence, 
the male:female ratio based on the life table cancer risk is higher than the ratios based 
on the other measures commonly used in descriptive epidemiology, for example, the 
age adjusted incidence rates or the cumulative risk. For example, the male:female ratio 
for the age adjusted incidence rate according to the European Standard Population is 
1.43, while the ratio for the life-table cancer risk is estimated to be 1.14. 
When calculating the individual risk, we considered only the first primary invasive malig­
nancy to be eligible. In 1989 and 1990 together, 7% of all the invasive malignancies 
recorded by the IKL cancer registry were second or subsequent cancers. When these 
second primary malignancies were included in the estimates, the lifetime risk increased 
from 34.8% to 38.0% for males and from 30.4% to 32.7% for females. 
All life table risk estimates are based on incidence rates. Theoretically, incidence rates 
are calculated as the ratio between the number of new cancer cases and the number of 
person years free from cancer. However, a population derived from a population regis­
ter will include prevalent cancer cases. Therefore, the true incidence of cancer will be 
underestimated. 
This phenomenon affects the cumulative rate and risk. Thus, although these methods 
overestimate the risk (because they are conditional on survival), the estimates would be 
even be higher if they were based on prevalence adjusted incidence rates. 
Feuer et al recently suggested a method for correcting these prevalent cases when 
calculating the life table cancer risk [6]. They calculated the number of expected cancer 
cases in the cohort as being the product of the age specific incidence rates and the 
number of persons in the cohort alive and free from cancer. The correction for prevalent 
cancer cases was performed by multiplication by the ratio R of the number alive at age 
χ and the number alive and free from a given type of cancer at age x. A reanalysis of 
our data using this correction for prevalent cases did not, however, change our results 
significantly. This can be explained by an inherent correction for prevalent cases with 
the life table method. The number of expected cancer cases is calculated as the product 
of the (underestimated) incidence rates and the number of person years. In these 
person years, the prevalent cancer cases are also included. 
It is possible to calculate the lifetime risk of developing cancer using the life table 
method because the number of person years and the cancer incidence rates in the very 
elderly are known. The lifetime risk represents the average risk at birth that a member of 
the cohort will develop cancer during his or her lifetime. 
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It seems remarkable that the risk of developing cancer during an individual's remaining 
lifetime rises until a certain age (see Figures 7.3 and 7.4). This can be explained by the 
fact that the number of cancer cases (the numerator) decreases only slowly with 
increasing age early in life (most of the cancer cases occur at advanced ages), while 
the number of persons alive and free from cancer (the denominator) decreases rapidly 
with increasing age. This phenomenon is especially notable for prostatic cancer, where 
the risk of developing cancer during the remaining lifetime rises until the age of 60 
years. 
Although the life table method has clear advantages compared to the cumulative risk 
method, it cannot replace the other two epidemiological measures [5]. Firstly, life 
expectancy tables are not available for all populations. Secondly, age adjusted incid-
ence rates, the cumulative risk and the cumulative rate are better suited for comparing 
the cancer incidence rates of different populations in different time intervals and at 
different locations. The fact that these measures are not adjusted for life expectancy 
means that they are more suitable for making direct comparisons of cancer occurrence 
between different populations. For example, an increasing life expectancy (fewer deaths 
from competing causes) with stable age-specific incidence rates will result in a higher 
estimate of the lifetime risk calculated with the life table, but will not influence the other 
risk estimates [5]. 
In conclusion, the life table method is a convenient method for estimating the probability 
that a person will develop cancer during a defined period or during his or her lifetime. 
The life table method is based on the assumption that the current death and cancer 
incidence rates will be maintained in the future, thus it shares this basic assumption with 
the other risk estimates. Because the life table method includes life expectancy, it is a 
good method for estimating the 'cancer burden' in a population. Other risk estimates 
overestimate the risk of developing any given disease, especially at advanced ages. 
The life table method cannot replace age standardized incidence rates. 
Acknowledgements 
We are grateful to the Central Bureau of Statistics and the Comprehensive Cancer 
Centre IKL (Integraal Kankercentrum Limburg) for providing the data. The Comprehens-
ive Cancer Centres IKL and IKO (Integraal Kankercentrum Oost) are acknowledged for 
providing financial support. We thank J. Abma-Hill for linguistic comments. 
74 Chapter 7 
Addendum 
List of notations: 
cK = number of incident cancer cases in age group x, obtained from the cancer 
registry. 
Cft = number of persons who develop cancer in the hypothetical cohort in a defined 
life period. 
I'x = life table population at age χ alive and free from cancer. 
nx = number of inhabitants in the area of the cancer registry in age group x, 
obtained from the Bureau of Statistics. 
Pcra = cumulative rate. 
Pcn = cumulative risk. 
Ρ,, = life table risk of developing cancer in a defined period. 
у
ж
 = total person years in the hypothetical cohort in age group x. 
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Abstract 
Purpose To study whether adjuvant treatment of early breast cancer with high-dose 
medroxyprogesterone acetate (MPA) has an effect on the incidence of contralateral 
breast cancer (CLBC). 
Patients and methods Data were used from a clinical study that was designed to invest-
igate the effect of high-dose MPA on disease free and overall survival. Women under 71 
years of age with stage l-lll breast cancer were eligible. 866 patients with breast cancer 
were entered into the study, of whom 463 had positive lymph nodes (or stage III). Of the 
patients with positive lymph nodes (or stage III), 234 received chemotherapy without 
MPA and 229 chemotherapy with MPA (determined by randomization). The median 
follow-up time was 78 months. After a histologic review 45 cases of contralateral dis-
ease were considered to be new primary cancers. CLBC incidence in different treatment 
groups was analyzed using actuarial methods and the proportional hazards model. 
Results The risk ratio (RR) of CLBC cases for high-dose MPA added to adjuvant 
chemotherapy was estimated at 0.5 (95% Confidence Interval 0.2-1.3). The protective 
effect was restricted to postmenopausal women (RR 0.2, 95%CI 0.04-0.8), whereas in 
premenopausal women the RR of high-dose MPA was estimated at 1.9 (95%CI 
0.6-6.4). 
ConclusionTbe study indicates that high-dose MPA has a protective effect on the risk of 
contralateral disease in postmenopausal women treated for breast cancer. Because of 
the small number of cases in this study, further confirmation of these results is needed. 
Important issues are whether the effect of MPA is related to dose and whether the effect 
will persist over time. 
Introduction 
Breast cancer is the most common cancer in females in nearly all industrialized coun-
tries. In the Netherlands, more than 30% of all diagnosed cancers in females are 
located in the breast [1]. The survival of women with breast cancer is relatively good, 
and has improved because of early detection and the introduction of adjuvant cytotoxic 
and hormonal therapy [2]. However, a substantial proportion of breast cancer patients 
develop a new cancer in the contralateral breast. Breast cancer patients are two to five 
times more likely to develop contralateral breast cancer (CLBC) than are women of the 
same age without breast cancer to develop an initial breast cancer [3]. Therapy of the 
first primary breast cancer is known to influence the risk of developing CLBC. Adjuvant 
cytotoxic [4-7] and hormonal therapy with tamoxifen [8-10] seem to diminish the risk of 
CLBC by about 30 to 50%. Besides tamoxifen, high-dose medroxyprogesterone acetate 
(MPA) is also used as hormonal treatment in advanced [11-13] 
and early breast cancer [14-16]. The relation between high-dose MPA as adjuvant hor-
monal treatment in early breast cancer and the subsequent risk of developing CLBC 
has not been studied, despite concern that it may induce breast cancer. MPA was found 
to be associated with the development of benign and malignant breast tumors in 
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beagles [17]. Low-dose depot MPA has been used by many women worldwide as a 
contraceptive. In a case-control study in Costa Rica [18] a significantly elevated risk of 
breast cancer was observed in depot MPA users compared to non-users. This result 
was not confirmed in two more recent studies [19,20]. However, the results of the latter 
two studies suggested higher risk estimates in some subgroups [19,20]. 
The purpose of this study is to investigate the effect of high-dose MPA on the risk of 
CLBC in premenopausal and postmenopausal women using data from a clinical breast 
cancer study conducted in the Netherlands. The primary research question of this study 
regarded disease free and overall survival. High-dose MPA used as adjuvant treatment 
reduced the risk of distant metastasis and improved survival in postmenopausal women, 
but is inactive and possibly detrimental in premenopausal patients [15,16]. 
The results of this analysis are not only relevant for patients with breast cancer but may 
also apply for those using synthetic progestogens for endometrial cancer or synthetic 
progestogens combined with estrogens as hormone replacement therapy after meno­
pause. 
Patients and methods 
Patients Women under 71 years of age with stage I, II, or III (according to TNM) [21] 
breast cancer were eligible for the study (Figure Θ.1). Women with bilateral breast 
cancer at diagnosis, with inflammatory carcinoma, or with contraindications for chemo­
therapy were ineligible. Also, patients with a prior malignancy (other than a non-melan­
oma skin cancer or a non-invasive cervical carcinoma) were not eligible for the study. 
The study was open for accrual from May, 19Θ2 until July, 1987. 
According to the study protocol, breast cancer was treated with a modified radical 
mastectomy or lumpectomy with postoperative irradiation. Lumpectomy was performed 
optionally in patients with a primary tumor of 2 centimeters or smaller. Patients with 
lymph node-positive breast cancer were treated with six 28-day cycles of adjuvant 
chemotherapy. Each cycle consisted of cyclophosphamide 500 mg/m2 intravenously 
(i.v.) on day 1, doxorubicin 40 mg/m2 i.v. on day 1, and 5-fluorouracil 500 mg/m2 i.v. on 
day 1. Randomization determined whether or not lymph node-positive patients also 
received MPA. MPA (Farlutal®) was administered daily in a dose of 500 mg intramuscu­
larly on days 1 through 28 and twice a week thereafter for a total period of six months 
[15]. The total administered dose accumulated to 36 000 mg over six months. 
Radiotherapy was not routinely added to the primary treatment. Breast radiotherapy 
was administered to patients with a lumpectomy (N=183), and/or parasternal radiother­
apy was given to patients with a median location of the tumor (N=221 ). In a small minor­
ity of patients (N=50) radiotherapy to the chest wall and/or regional node therapy was 
given because of dubious resection margins, tumor spill or a very large tumor load. 
Patients eligible for the study had to be reported to the Comprehensive Cancer Center 
Limburg (IKL) before their surgery. Patients were then randomized with respect to the 
hormonal therapy by the Centre. The patients with positive lymph nodes and the relev­
ant randomization received MPA after surgery. 
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Figure 8.1 : Study design 
Notes: *= Radiotherapy if indicated; #=Cyclofosfamide, doxorubicine and 5-fluorouracil. 
Follow-up included a history and physical examination every three months during the 
first two years, every four months in the third year, every six months in the fourth and 
fifth years, and every year thereafter. A mammography of the contralateral (not affected) 
breast was performed every year. 
Data collection Information about anamnestic and diagnostic data was collected and 
recorded by the treating physician. Information with respect to the follow-up (vital status, 
occurrence of recurrences, and CLBC) was collected by the principal investigators (L.S., 
P.H., and J.J.) from the medical records. Also, the anamnestic and diagnostic data were 
checked and completed by the investigators if necessary. When follow-up information 
was missing, the patient's general practitioner was contacted. At July 1, 1992 the vital 
status was known of 96.0% of all patients entered into the study. 
A patient was regarded as postmenopausal when her last menstruation had occurred 
more than one year before diagnosis of the first breast cancer. In case of missing 
information (N=24) in the medical records, patients older than fifty years of age were 
considered to be postmenopausal. 
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Contralateral breast cancer Second primary breast cancer was defined as a new prim-
ary breast cancer (not being a recurrence) in the contralateral breast. With data from the 
population-based cancer registry IKL [22] the completeness of cases of CLBC was 
checked. No additional cases were found. Histologic slides of the first and second 
breast cancers were simultaneously reviewed by one pathologist (E.T.). The presence 
of in-situ carcinoma in the second tumor or a difference in histological (sub)type [23] 
was considered to be evidence of a second primary carcinoma in the contralateral 
breast. In cases without CLBC follow-up was censored at the time of recurrence of the 
primary breast cancer or, when no recurrence had occurred, at death or at the last day 
known to be alive. 
Statistical analysis The influence of adjuvant chemotherapy, hormonal therapy, and 
other variables were primarily analyzed by calculating the incidence using actuarial 
methods and the logrank test [24]. The cumulative incidence was calculated as 
1-survival. To investigate effects of other variables on the risk of CLBC the Cox's 
Proportional Hazards Model was used. The analysis was performed using the PHREG 
procedure of SAS [25]. Undue influence of individual patients was checked using influ-
ence and residual plots [26]. The sensitivity of the estimated results was tested by 
removing or adding two CLBC cases at random. Inspection of log(-log) survival curves 
showed that the proportional hazards assumption was not fulfilled for the variable 
chemotherapy. Chemotherapy was therefore used as stratification variable in the 
models. In the simple models high-dose MPA, chemotherapy, and another character-
istic were entered as variables. In the comprehensive model high-dose MPA, chemo-
therapy, radiotherapy, menopausal status, age at diagnosis (three categories), weight 
(three categories), family history of breast cancer, number of children, and estrogen 
receptor content were entered as explanatory variables. The variables number of 
children and estrogen receptor content were removed from the model, because the 
p-values of the parameter estimates were not statistically significant and the removal of 
these variables did not influence the parameter estimates of the remaining variables in 
the model. A better fitting model was accomplished by introducing interaction terms for 
menopausal status with high-dose MPA and radiotherapy, respectively. 
Results 
From May 1982 until June 1987, 866 eligible patients were entered into the study. The 
median follow-up time was 78 months (maximum 142 months). Of the study group, 403 
patients were not treated with chemotherapy (because the axillary lymph nodes were 
free of metastasis) and 463 patients were treated with chemotherapy (because of meta-
stasis in the axillary lymph nodes or stage III breast cancer). Of the 463 patients treated 
with chemotherapy, 229 were additionally treated with high-dose MPA, allocated by 
randomization (see Table 8.1 ). The characteristics of the patients treated with or without 
MPA are in general well balanced. There are small differences between the treatment 
arms with respect to number of children, family history, and menopausal status. 
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Table 8.1: 
Characteristics of patients according 
Characteristics 
Total 
Menopausal status 
Pre 
Post 
Radiotherapy 
Yes 
Age at diagnosis (years) 
<34 
35-50 
51-70 
mean (st.dev.) 
Tumor stage [21] 
I 
II 
III 
Estrogen receptor (fmol/mg 
0-150 
>150 
unknown 
Weight (kg) 
<63 
63.1 -<82 
>82.1 
unknown 
mean (st.dev) 
Family history 
negative 
positive 
unknown 
Number of children 
0 
£1 
unknown 
Follow up time (months) 
<48 
49-96 
>97 
median 
Recurrences 
loco-regional 
distant 
Contralateral breast cancer 
all 
histological verified 
to treatment 
No chemotherapy MPA 
N (%) N 
403 234 
158 
245 
248 
14 
150 
239 
52.8 
182 
221 
— 
282 
72 
49 
146 
198 
32 
27 
66.2 
333 
57 
13 
74 
324 
5 
96 
138 
169 
90 
24 
83 
29 
26 
(39.2) 
(60.8) 
(61.5) 
(3-5) 
(37.2) 
(59.3) 
(9.9) 
(45.2) 
(54.8) 
H 
(70.0) 
(17.9) 
(12.2) 
(36.2) 
(49.1) 
(7.9) 
(6.7) 
(11.2) 
(82.6) 
(14.1) 
(3.2) 
(18.4) 
(80.4) 
(1.2) 
(23.8) 
(34.2) 
(41.9) 
H 
(6.0) 
(20.6) 
(7.2) 
(6.5) 
81 
153 
73 
9 
78 
147 
53.0 
31 
178 
25 
175 
44 
15 
76 
125 
23 
10 
68.0 
196 
29 
9 
43 
188 
3 
119 
65 
50 
46 
37 
108 
14 
12 
Chemotherapy 
H MPA (+) 
(%) 
(34.6) 
(65.4) 
(31.2) 
(3.8) 
(33.3) 
(62.8) 
(9.6) 
(13.2) 
(76.1) 
(10.7) 
(74.8) 
(18.8) 
(6.4) 
(32.5) 
(53.4) 
(9.8) 
(4.3) 
(10.8) 
(83.8) 
(12.4) 
(3.8) 
(18.4) 
(80.3) 
(1.3) 
(50.9) 
(27.8) 
(21.4) 
H 
(15.8) 
(46.2) 
(6.0) 
(5.1) 
Ν 
229 
87 
142 
68 
8 
88 
133 
52.4 
31 
169 
29 
167 
49 
13 
86 
114 
21 
8 
67.8 
186 
37 
6 
35 
190 
4 
102 
69 
58 
63 
35 
92 
8 
7 
(%) 
(38.0) 
(62.0) 
(29.7) 
(3.5) 
(38.4) 
(58.1) 
(9.9) 
(13.5) 
(73.8) 
(12.7) 
(72.9) 
(21.4) 
(5.7) 
(37.6) 
(49.8) 
(9.2) 
(3.5) 
(11.5) 
(81.2) 
(16.2) 
(2.6) 
(15.3) 
(83.0) 
(1.7) 
(44.5) 
(30.1) 
(25.3) 
Η 
(15.3) 
(40.2) 
(3-5) 
(3.1) 
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In the 866 patients, 51 cases of CLBC were diagnosed during follow-up. Of 49 cases, 
the histology slides of both breast cancers could be reviewed (of two cases one or both 
slides were missing). In 45 cases, histological evidence was found that the second 
breast cancer was a primary cancer. In the group not treated with chemotherapy, 26 
histologically verified second breast cancer cases were detected; in the group with 
chemotherapy alone 12 cases were detected, and in the group treated with chemo­
therapy and MPA, seven cases. 
In Figure 8.2 the cumulative incidence of CLBC is shown, according to treatment with 
chemotherapy and high-dose MPA. The cumulative incidence at 78 months (the median 
follow-up time) was estimated at 6.3% for the no-chemotherapy group, 7.4% for the 
chemotherapy-only group and 3.2% for the chemotherapy with MPA group. The differ­
ences between the estimates of the cumulative incidence in the three treatment groups 
were not statistically significant (logrank test: p=0.43). At nine years the cumulative 
incidence of CLBC in the patients treated with MPA increases sharply, but the number 
of patients at risk is small. 
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Figure 8.2: Cumulative incidence of contralateral breast cancer ¡η Θ66 patients with stage l-lll breast 
cancer according to adjuvant chemotherapy and hormonal treatment using actuarial methods 
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In the subgroup of postmenopausal women (Figure 8.3) the differences between the 
treatment groups were larger. At 78 months the cumulative incidence was estimated at 
7.1% for the no-chemotherapy group, 8.3% for the chemotherapy-only group and only 
1.4% for the chemotherapy with MPA group. Although a tendency towards a difference 
existed, this was not statistically significant (logrank test: p=0.095). 
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Figure B.3: Cumulative incidence of contralateral breast cancer in 540 postmenopausal patients with 
stage l-lll breast cancer according to adjuvant chemotherapy and hormonal treatment using actuarial 
methods 
To control for possible confounding, the incidence of CLBC was analyzed using the 
Cox's Proportional Hazards Model (Table 8.2) [24]. The risk ratio (RR) for high-dose 
MPA, without an interaction term for menopause, was estimated at 0.5 (95% Confid­
ence Interval 0.2-1.3). In the comprehensive model the risk ratio of high-dose MPA is 
estimated at 1.9 for premenopausal women (95% CI 0.6-6.4) and 0.2 for 
postmenopausal women (95% CI 0.04-0.8). Radiotherapy was related to the incidence 
of CLBC, but the direction of the effect was also dependent upon menopausal status. In 
premenopausal women the risk ratio was estimated at 4.1 (95% CI 1.2-13.9), in 
postmenopausal women at 0.6 (95% CI 0.4-0.7). 
High-dose MPA and contralateral breast cancer 
Table Θ.2: 
Risk ratios (RR) and 95% confidence intervals (95% CI) for contralateral breast cancer according to therapy, 
age at diagnosis, weight and family history Estimates from the Cox's Proportional Hazards model (N=866) 
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Variable 
High-dose MPA 
Radiotherapy 
Age at diagnosis 
(years) 
Weight (kg) 
Family history" 
Menopausal 
status 
Pre-
Post-
Pre-
Post-
-
-
-
Value 
No 
Yes 
No 
Yes 
No 
Yes 
No 
Yes 
<34 
35 -< 50 
>50 
<63 
63 -< 82 
>82 
missing 
Negative 
Positive 
Total 
(N) 
239 
87 
398 
142 
167 
159 
310 
230 
31 
316 
519 
308 
437 
76 
45 
743° 
121 
Cases 
(N) 
10 
5 
28 
2 
4 
11 
19 
11 
2 
10 
33 
21 
15 
8 
1 
35 
10 
RR" 
1 
1 5 
1 
0 2 
1 
3 0 
1 
06 
2 4 
1 
2 3 
1 9 
1 
3 4 
0 8 
1 
1 7 
95%CI 
Ref 
0 4-6 4 
Ref 
0 1-1 0 
Ref 
0 9-9 8 
Ref 
0 3-1 2 
0 5-11 3 
Ref 
1 1-4 6 
1 0-3 7 
Ref 
14-8 0 
0 1-6 1 
Ref 
0 8-3 5 
RR" 
1 
1 9 
1 
0 2 
1 
4 1 
1 
0 6 
2 2 
1 
4 0 
2 0 
1 
3 1 
0 8 
1 
1 9 
95%CI 
Ref 
0 6-6 4 
Ref 
0 0-0 8 
Ref 
1 2-13 9 
Ref 
0 4-0 7 
0 5-10 5 
Ref 
1 5-10 7 
1 0-4 0 
Ref 
1 3-7 3 
0 1-6 3 
Ref 
0 9-3 9 
a) adjusted for high-dose MPA and stratified for chemotherapy, b) Adjusted for all vanables in the table and 
menopausal status and stratified for chemotherapy, c) Reference category, d) Only relatives in the first degree 
(mother, sister, or daughter), e) Including 28 cases with missing information 
Besides therapy, items like age at diagnosis, weight, and family history were risk factors 
for developing CLBC in this study. The relation between age at diagnosis of the first 
breast cancer and the occurrence of CLBC seems to be U-shaped: elevated risks 
among younger and older age groups. The relation between weight and CLBC shows a 
comparable pattern. Women with a positive family history have an increased risk of 
CLBC. 
The results were not different when the analyses were performed using all 51 cases of 
CLBC, including the six cases which were not histologically verified. For all cases of 
CLBC the risk ratio of high-dose MPA was estimated to be 2.9 in premenopausal 
women (95% CI 0.9-9.4) and 0.1 in postmenopausal women (95% CI 0.03-0.6). 
Discussion 
This is the first study to demonstrate that high-dose MPA may protect against the occur­
rence of a second primary cancer in the contralateral breast in postmenopausal women 
In premenopausal women there was a non-significant increased risk of CLBC. 
This study has several advantages. First, all cases of CLBC were reviewed by one 
pathologist and strict criteria were used for the definition of CLBC. Second, the admmis-
84 Chapter 8 
tration of M PA was determined by randomization and most factors known to be related 
to the risk of CLBC could be adjusted for. 
A drawback of the study is the small number of events. This limited the possibilities for 
subgroup analyses and examination of interaction between variables. 
Although numbers are small, we did investigate the effect of high-dose MPA according 
to menopausal status, because of the heterogeneous effect observed in this study with 
respect to the major endpoints (survival and distant metastasis) [15,16]. Also, the 
protective effect of another hormone used in breast cancer treatment, tamoxifen, may 
be restricted to postmenopausal women [10,27]. 
The effect of high-dose MPA on the development of breast cancer in women has not 
been studied before. However, the protective effect of high-dose MPA in 
postmenopausal women in our study seems to contradict the results of the two latest 
case-control studies with respect to depot low-dose MPA [19,20,28]. In these studies no 
protective effect was found and a small elevated risk of primary breast cancer for cur-
rent or recent use of depot MPA in young women was observed. However, in our study 
MPA was administered short term in high doses and the protective effect was restricted 
to postmenopausal women. Our findings in premenopausal women are therefore not 
inconsistent with the results of the case-control studies [19,20,28]. 
The effect of low-dose MPA in postmenopausal women has been examined in only a 
few studies [29,30]. One study compared the incidence of breast cancer in 84 
postmenopausal women who used hormonal supplementation (estrogens and low 
doses of MPA) to 84 matched controls that used no supplementation. After a follow-up 
of 22 years in the control group six cases of breast cancer were detected, while in the 
group with hormonal supplementation no cases were found [29]. Because of limited 
power and uneven distribution of groups according to possible confounders, this study 
yielded no definitive conclusion. In a recent study the effect of adding progestins to 
estrogen replacement therapy in postmenopausal women was reported [30]. The risk of 
breast cancer was increased among women using estrogens alone, but this risk was not 
reduced by the addition of progestins. The proportion of women that used low-dose 
MPA as progestin was not stated. 
In animal studies, the results with respect to MPA and the development of breast cancer 
are inconsistent. Some of the earliest studies were performed on beagles and gave rise 
to concern about a possible elevated risk of breast cancer in relation to MPA. The 
beagle, however, is currently not considered to be an adequate model for human breast 
cancer In rats, low-dose MPA seems to inhibit the development of mammary tumors 
induced by dimethyl-benz(a) anthracene (DMBA), administered one week after MPA 
[32]. Tumor incidence was lowest with a controlled release of low doses of MPA. More-
over, mammary tumors in rats treated with MPA were smaller in size [32]. In another 
study, MPA was administered six to three weeks before DMBA to virgin rats [33]. In low 
doses no effect of MPA was observed, whereas in higher doses the incidence of 
mammary tumors was increased. In mice, MPA enhanced the incidence of mammary 
tumors [34,35]. 
Our findings with regard to other risk factors are generally in accordance with other 
studies [3]. Among postmenopausal women a high body mass index has been shown to 
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be associated with an increased risk to develop a first breast cancer, whereas among 
premenopausal women an inverse relationship has been found [36]. Body mass or 
weight have been associated also with the risk of CLBC in some, but not all studies [3]. 
The elevated risk among women with low weight has not been reported earlier, and may 
just reflect chance. 
The relation between age at diagnosis of the first breast cancer and the occurrence of 
CLBC in this study seems to be inconsistent with other studies. In most studies, the 
relative risk is the highest in the youngest age group and decreases with increasing age 
[3]. Most previous studies have analyzed relative risks by age compared to general 
population expectations, while we have analyzed age-specific risks between groups 
within the study [37]. 
Radiotherapy was related to an elevated risk in premenopausal women and a risk 
reduction in postmenopausal women. Several studies have not found an elevated risk 
for CLBC with radiotherapy, but these analyses were not stratified by menopausal 
status [4,5,38,39]. In a recent study an increased risk was reported for women treated 
before the age of 45 years [40]. This risk followed a dose-response pattern and was 
especially large for women who survived longer than 10 years after treatment. 
The possible protective mechanism of MPA remains unclear. The protective effect in 
our study is limited to postmenopausal women, which suggests that it is not mediated 
through the ovaries. A direct cytotoxic effect on breast cells, therefore, seems to be 
more likely. MPA binds to progesterone, androgen and Cortisol receptors with high 
affinity [41]. Such binding may result in decreased synthesis of estrogen receptors, 
making tumor cells less responsive to endogenous estrogen. Also, MPA reduces the 
serum levels of estrogens by influencing the pituitary adrenal axis [42,43]. Especially in 
postmenopausal women there is substantial evidence that high estrogen levels are 
associated with an increase in breast cancer risk [44]. 
In premenopausal women MPA possibly increases the risk of CLBC. This can be 
explained by a protective effect on the ovarian function during the chemotherapy, which 
prevents chemotherapy-induced ovarian ablation [45]. Early menopause reduces the 
risk of breast cancer [46], and women using high-dose MPA may not benefit from this 
reduction of risk. 
The protective effect in postmenopausal women, and the possibly harmful effect in 
premenopausal women, is in accordance with the finding that MPA in the case of 
adjuvant treatment affects distant metastasis and improves survival in postmenopausal 
women, but is inactive and possibly detrimental in premenopausal patients [15,16]. 
In summary, in this study a protective effect of high-dose MPA on the incidence of 
breast cancer was observed in postmenopausal women and a possibly harmful effect in 
premenopausal women. Confirmation of these findings in other studies is needed, and 
longer follow-up of the present study will show whether the MPA effects on CLBC risk 
persist over time. Other important questions are whether the effects are dependent 
upon dose intensity and duration of treatment. 
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List of used abbreviations 
CLBC 
CI 
DMBA 
ι V 
mg 
MPA 
Ref 
RR 
= Contralateral Breast Cancer 
= Confidence Interval 
= dimethyl-benz(a) anthracene 
= intravenously 
= milligrams 
= Medroxyprogesterone acetate 
= Reference category 
= Risk Ratio 
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Abstract 
Several risk factors for the etiology of breast cancer have also been correlated with the 
prognosis of breast cancer. However, the published studies have yielded conflicting 
results. 
Women under 71 years of age with stage I, II, or III breast cancer were eligible for 
inclusion in a clinical study. 866 patients with breast cancer entered the study, of whom 
463 had positive lymph nodes. Survival was analysed using Cox's proportional hazards 
model. 
Age at menarche, parity, age at menopause and family history were not consistently 
related to survival. Young age at first full-term pregnancy was related to decreased 
survival (adjusted relative risk (RR): 1.69, 95% confidence intervals (95% CI): 1.04-
2.68). Use of oral contraceptives was not correlated with survival (RR: 1.10, 95% CI: 
0.80-1.51) nor was family history (RR: 0.93, 95% CI: 0.66-1.30). 
This study provided little support for the hypothesis that risk factors for breast cancer 
are related to survival. 
Introduction 
The etiology of breast cancer has been studied extensively and many risk factors have 
been established, such as family history of breast cancer, specific benign breast 
diseases, race, parity, age at first full-term pregnancy, age at menarche, age at meno-
pause and obesity [1]. It is not unlikely that some of these risk factors promote the 
development of specific types of breast cancer with differences in prognosis as a con-
sequence. Also, several of the known risk factors implicate that endogenous hormones 
are involved [2]. The same risk factors may therefore also influence the course of the 
disease. 
With the exception of obesity [3], the prognostic significance of etiological risk factors 
has not been studied very often. The few studies that have been published, yielded 
conflicting results. In several studies, but not in all, age at menarche, number of full-term 
pregnancies, age at first pregnancy and the use of oral contraceptives were related to 
survival [4-10]. 
We studied the effects of etiological risk factors on the prognosis of breast cancer 
patients who entered a large multicenter clinical study in the Netherlands [11]. 
Subjects and method 
Patients Women under 71 years of age with stage I, II, or III (according to TNM [12]) 
breast cancer were candidates for the multicentre clinical study. Women with bilateral 
breast cancer, inflammatory carcinoma, or contraindications for chemotherapy were 
ineligible. Also, patients with a prior malignancy (other than non-melanoma skin cancer 
or non-invasive cervical carcinoma) were not eligible for the study. The trial was open 
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for accrual from May 1982 until June 1987. According to the study protocol, breast 
cancer was treated with lumpectomy with postoperative irradiation or a modified radical 
mastectomy. Patients with positive lymph nodes and/or stage T4 breast cancer were 
also treated with six cycles of (adjuvant) chemotherapy (cyclophosphamide, doxorubicin 
and 5-fluorouracil). Randomization of the positive lymph node patients determined who 
received medroxyprogesterone acetate (MPA) in addition to chemotherapy. If indicated, 
radiotherapy was added to the primary treatment. Details of this study have been 
published previously [11]. From May 1982 until June 1987, 866 patients entered the 
study. 
Dafa collection Data on the medical history, physical examination, diagnostic work-up 
and the presence of etiological risk factors were recorded by the treating physician on 
the study form. Information with respect to follow-up (vital status, tumour recurrences, 
metastases) were extracted from the medical records by the principal investigators 
(LS., P.H. and J.J.). If follow-up information was missing, the patient's general practi-
tioner was contacted. On 1 July 1992 the vital status was known in 95.0% of the 
patients who entered the study. 
Statistical analysis Survival was analysed with the Kaplan-Meier method and the 
logrank test. Death from breast cancer was chosen as the endpoint. Patients who died 
from other causes were censored on the date of death. To investigate the effects of 
other variables on survival, Cox's proportional hazards model was used [13]. The ana-
lysis was performed using the PHREG procedure of SAS [14]. Log(-log) survival curves 
were inspected to check the proportional hazards assumption essential to Cox's pro-
portional hazards model. 
Results 
The median follow-up of the 866 patients was 89 months (maximum 142 months). A 
total of 463 patients were treated with chemotherapy and 403 patients were treated 
without. In the subgroup of 463 patients treated with chemotherapy, 229 received addi-
tional high-dose MPA over a period of six months, allocated by randomization. In the 
total study group, 293 breast cancer related deaths were recorded. 
Survival was poorest in patients with more advanced stage, a larger number of positive 
axillary lymph nodes, low oestrogen and progesterone receptor status, DNA aneuploidy 
and women of younger and older age (Table 9.1). 
Only a few of the etiological risk factors of the patients were related to survival itself 
(Table 9.2). When age at menarche of 13 years was chosen as a reference category, 
both a younger and a older age at menarche had a lower relative risk of breast cancer 
related death. Only an estimated age at menarche of 15 years differed statistically 
significantly from unity. However, when age at menarche was 16 years of age or older, 
the relative risk was once again close to unity. Therefore, no consistent trend could be 
observed. 
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Table 9.1: 
Risk ratio of breast cancer related death according to clinical characteristics of 866 patients with early breast 
cancer 
Charactenstic 
Clinical stage 
Number of pos 
lymph nodes 
Oestrogen receptor 
status (fmol/mg) 
Progesterone 
receptor status 
DNA ploidy 
Age 
Adjuvant therapy" 
Category 
l(T,) 
"(Т
г
з) 
III (T4 or N J 
< 4 
> 4 
<10 
>10 
? 
< 10/'° 
>10 
diploid 
aneuploid 
missing 
<40 yrs 
40-54 yrs 
> 55 yrs 
No 
FAC 
FAC+MPA 
Number of 
deaths/patients 
42/244 
169/493 
82/129 
179/687 
114/179 
132/237 
181/552 
16/77 
172/473 
121/393 
57/240 
160/414 
76/212 
39/92 
105/373 
149/401 
77/403 
115/234 
101/229 
Unadjusted 
RR* (95% CI) 
1 (Ref) 
2 25(1 61-3 16) 
6 13(4 22-8 91) 
1 (Ref) 
2 31 (1 77-3 03) 
1 (Ref) 
0 68 (0 53-0 88) 
0 42(0 25-0 71) 
1 (Ref) 
0 80(0 63-1 01) 
1 (Ref) 
1 91 (1 41-2 58) 
1 70 (1 20-2 39) 
1 57(1 08-2 26) 
1 (Ref) 
1 37 (1 06-1 75) 
1 (Ref) 
3 29 (2 46-4 39) 
2 85(2 12-3 83) 
Adjusted 
RRb(95%CI) 
1 (Ref) 
1 61 (1 12-2 32) 
3 27(214-4 99) 
1 (Ref) 
2 21 (1 68-2 91) 
1 (Ref) 
0 70 (0 54-0 92) 
0 50 (0 29-0 85) 
1 (Ref) 
0 76 (0 59-0 98) 
1 (Ref) 
1 34 (0 99-1 83) 
1 36 (0 96-1 94) 
1 81 (1 25-2 64) 
1 (Ref) 
1 22 (0 95-1 58) 
1 (Ref) 
1 77 (1 26-2 48) 
1 50(1 06-2 12) 
Notes a) RR= Relative risk, 95% Cl= 95% Confidence Interval, Ref= Reference category, b) Adjusted for the 
other characteristics in the table, c) Unknown PR was combined with PR <10 fmol/mg, because the estimates 
of risk were the same, d) FAC= adjuvant chemotherapy, MPA= medroxyprogesterone acetate (adjuvant 
hormone therapy) 
Young age at first full-term pregnancy seemed to be correlated with the prognosis. 
Survival was poorer in breast cancer patients aged 22 years or younger at first full-term 
pregnancy (unadjusted relative risk (RR): 1.59, 95% confidence intervals (95% CI): 
1 00-2.53) than in patients of 30 years and older at first full-term pregnancy. Adjusted 
for the other clinical characteristics, the relative risk was estimated at 1.67 (95% CI: 
1.04-2.68). 
Number of full-term pregnancies, age at menopause, use of oral contraceptives and 
family history (Table 9.2) did not seem to be related to breast cancer survival. With 
respect to the use of oral contraceptives, also duration and recency of use were studied 
(Table 9.3). Duration of use was not consistently related with breast cancer survival, 
with a small non-significant increased relative risk for a use of 1-5 years (unadjusted RR 
1 23; 95% CI 0.65-2.30). Recency of use showed only small statistically non-significant 
departures from unity. 
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Table 9.2: 
Relative nsk of death from breast cancer according to reproductive characteristics of 866 patients with early 
breast cancer 
Characteristic 
Age at menarche 
Children 
Age at first full-term 
pregnancy 
Number of 
children 
Menopause status 
Age at menopause 
Use of oral 
contraceptives 
Family history' 
Category 
< 11 yrs 
12yrs 
13 yrs 
14 yrs 
15 yrs 
> 16 yrs 
missing 
no 
yes 
missing 
< 22 yrs 
23-24 yrs 
25-26 yrs 
27-29 yrs 
¿ 30 yrs 
missing 
1-3 
¿4 
missing 
pre 
post 
< 45 yrs 
46-48 yrs 
49-51 yrs 
52-53 yrs 
> 54 yrs 
missing 
never 
periodically 
missing 
no 
yes 
missing 
Number of 
deaths/patients 
21/68 
31/90 
65/182 
44/141 
18/83 
30/51 
84/251 
51/152 
237/702 
5/12 
49/113 
32/112 
38/114 
44/127 
28/95 
46/141 
185/552 
52/150 
5/12 
106/326 
187/540 
38/109 
26/79 
37/106 
29/86 
23/62 
36/110 
196/594 
58/180 
39/92 
245/723 
40/123 
8/20 
Unadjusted 
RR* (95% CI) 
0 68(0 42-1 12) 
0 80 (0 52-1 23) 
1 (Ref) 
0 70 (0 48-1 03) 
0 46 (0 27-0 77) 
0 92(0 60-141) 
0 77 (0 56-1 06) 
1 (Ref) 
0 94 (0 69-1 27) 
1 76(0 70-4 41) 
1 59 (1 00-2 53) 
0 93 (0 56-1 54) 
1 10(0 68-1 79) 
1 14(0 71-1 83) 
1 (Ref) 
1 13(0 71-1 80) 
1 (Ref) 
1 13(0 87-145) 
1 98(0 81-4 85) 
1 (Ref) 
1 08 (0 85-1 37) 
1 (Ref) 
1 06 (0 66-1 73) 
1 07 (0 68-1 68) 
1 00 (0 62-1 62) 
1 05 (0 63-1 77) 
0 92 (0 57-1 47) 
1 (Ref) 
0 96 (0 72-1 29) 
1 41 (1 00-1 99) 
1 (Ref) 
0 92 (0 66-1 28) 
1 78 (0 88-3 60) 
Adjusted 
RRb(95%CI) 
0 79 (0 48-1 30) 
0 70 (0 46-1 08) 
1 (Ref) 
0 67 (0 27-0 99) 
0 45 (0 27-0 77) 
0 83 (0 54-1 29) 
0 84(0 60-1 17) 
1 (Ref) 
0 91 (0 67-1 24) 
1 68 (0 67-4 27) 
1 67 (1 04-2 68) 
0 92 (0 55-1 55) 
1 03 (0 63-1 70) 
1 01 (0 63-1 63) 
1 (Ref) 
1 37(0 86-2 19) 
1 (Ref) 
1 18(0 90-1 55) 
2 03 (0 82-5 03) 
1 (Ref) 
0 87 (0 60-1 26) 
1 (Ref) 
0 80 (0 48-1 32) 
0 81 (0 50-1 32) 
0 44 (0 26-0 76) 
0 72(0 41-1 26) 
0 66 (0 40-1 08) 
1 (Ref) 
1 10(0 80-1 51) 
1 68(1 18-2 38) 
1 (Ref) 
0 93 (0 66-1 30) 
1 88 (0 92-3 87) 
Notes a) RR= Relative nsk, 95% Cl= 95% Confidence Interval, Ref= Reference category, b) Adjusted for the 
clinical characteristics in table 9 1, c) Relatives first grade (mother, daughter, sister) with breast cancer 
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Table 9.3: 
Relative nsk of dying from breast cancer according to duration and recency of oral contraceptive use in 180 
patients with early breast cancer who had used oral contraceptives periodically 
Characteristic 
Duration of use 
Recency of use 
Value 
<1 yr 
1 -5 yrs 
>5yrs 
missing 
<1 yr 
1 -5 yrs 
>5yrs 
missing 
Number of 
deaths/patients 
21/70 
18/52 
15/48 
4/10 
9/27 
8/28 
26/77 
15/48 
Unadjusted 
RRa(95%CI) 
1 (Ref) 
1 23 (0 65-2 30) 
1 03 (0 53-2 00) 
1 51 (0 52-4 41) 
1 (Ref) 
0 83(0 32-2 15) 
1 04 (0 49-2 22) 
0 98 (0 43-2 23) 
Adjusted" 
RR (95% CI) 
1 (Ref) 
1 62(0 83 3 15) 
0 95 (0 47-1 92) 
1 63 (0 50-5 28) 
1 (Ref) 
1 23 (0 46-3 28) 
0 82 (0 36-1 85) 
1 18(0 50-2 78) 
Notes a) RR= Relative nsk, 95% Cl= 
clinical features in Table 9 1 
95% Confidence Interval, Ref= Reference category, b) Adjusted for the 
Discussion 
This study yielded little evidence that etiological risk factors are related to the survival of 
breast cancer patients. Age at menarche, number of full-term pregnancies, age at 
menopause, previous use of oral contraceptives and family history were not consistently 
related to breast cancer survival, with the possible exception of age at first full-term 
pregnancy. 
Young age at first full-term pregnancy was related to shorter survival. This result is 
comparable with the findings in one other study, in which survival rates were increased 
with increasing age at pregnancy [7]. In this study only premenopausal women were 
studied Other studies were unable to find a relation between age at first pregnancy and 
survival [9,15-18]. Age at first pregnancy seems to be related to prognosis, but in view 
of the fact that the majority of studies did not report a relation, it cannot be excluded that 
our results were due to chance. 
The relation between parity or gravidity and breast cancer survival is also heterogen-
eous. Some publications did not find a relation [9,15,17,19], one study reported better 
survival in parous women [5], while most studies reported poorer survival in all parous 
women [6,18] or in some subgroups [16,20,21]. In our study no relation was demon-
strated between increasing parity and survival. 
Age at menarche was found to be related to survival in three studies [4,6,17], whereas 
in some other studies no relation could be demonstrated [7,9,18,21,22] The studies that 
linked age at menarche with survival showed conflicting results. Patients of 11 years or 
younger at menarche had the poorest survival in one study [4]. The difference in 
survival rate was statistically significant after three years of follow-up, but this was no 
longer the case after five years. In the other studies, survival improved with increasing 
age at menarche [17], or survival was poorest in women aged 16 years or older at 
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menarche [6]. The inconsistent outcomes published in the literature and the lack of any 
consistent trend in this study do not support a relation between age at menarche and 
breast cancer survival. 
Age at menopause does not seem to affect breast cancer survival significantly. This was 
also found in some other publications [6,21]. 
In the seventies and the first half of the eighties it was widely believed that the use of 
OCs could have an adverse effect on the prognosis of breast cancer [23-25]. The first 
studies that were published with respect to the possible effects of prior OC use on the 
prognosis of breast cancer could not demonstrate any effect of OCs on the prognosis 
[7,26-28]. However, the power of these studies was small and the follow-up was 
relatively short. A Swedish study suggested that age at the start of OC use was essen-
tial. Survival was significantly poorer in women who had started using OCs before the 
age of 20 years [29,30]. A few other studies also reported small but not significant 
adverse effects of OCs on the prognosis of breast cancer [18,31]. These findings were 
not confirmed in the most recent studies. In a Danish study, OCs were not found to 
affect the prognosis [9]. Two studies suggested that use had a favourable influence on 
the prognosis of breast cancer [10,32]. The age at which OC use was started did not 
influence the prognosis [10]. However, in these studies the large majority of women had 
used OCs at some time in the past. It can be argued therefore that women who have 
not used OCs are a specific subgroup with different characteristics. In our study no 
relation could be demonstrated between the prior use of OCs and the prognosis of 
breast cancer. Duration and recency of use were not related to survival either. 
A family history of breast cancer was not related to survival. In the literature family 
history was found to be related to better [33] and poorer [18,34] survival. However, most 
of the publications did not mention any relation [5,7,35,36]. 
This study provided little support for the hypothesis that risk factors for breast cancer 
are related to survival. The negative result cannot be explained by a lack of power or 
too short follow-up. Assuming an exposed proportion of 25%, the power of this study 
was 90% to demonstrate a relative risk of 1.6 [37]. Also, a median follow-up of 89 
months and 293 breast cancer related deaths (34% of all cases) seem to be sufficient to 
demonstrate a clinically relevant difference in survival. 
Exposure to most risk factors will have occurred prior to the detection of breast cancer. 
Any effect on progression will therefore be mediated through the biological character-
istics of the tumour. In this case adjusting for these variables would not be correct, as 
they are not confounding, but intermediate variables. However, in this study univariate 
and multivariate effect measures of survival failed to suggest a relation between the risk 
factors studied and breast cancer survival. A relation found by others between body size 
indicators and breast cancer survival may be an exception [3]. With respect to this 
variable it has been hypothesized that in overweight breast cancer patients, the pro-
gnosis is affected by a higher production of extra-ovarian oestrogens in fat cells; this 
increased exposure will continue after diagnosis [22]. Apparently, other risk factors also 
affect the etiology of breast cancer, but do not lead to grossly different types of breast 
cancer or to large differences in survival. 
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This thesis evaluated the quality and use of the data recorded by the recently estab-
lished Netherlands cancer registry and the role of the registry in relation with clinical 
studies. In this chapter, the results of the studies and the future of the cancer registry 
are discussed. Finally, some recommendations are made for future research. 
Quality control 
The completeness of case ascertainment of the regional cancer registry IKL was estim-
ated to be 96.2% for the incidence years 1988-1990. This estimate is comparable with 
other cancer registries that have a good reputation [1,2,3]. Missed records could be 
attributed to systematic deficiencies (e.g., patients not referred to the hospitals or 
patients treated outside the catchment area) and to errors in the notification procedures. 
Since the completion of the study, registry procedures have been improved even further 
and various systematic deficiencies have been resolved. Starting in 1989, all regional 
cancer registries have been submitting their data to the central national cancer registry 
and any information about patients treated outside the catchment areas is exchanged 
[4]. 
A recent comparison of data with respect to childhood leukaemia has also suggested 
that completeness has improved [5]. In the IKL study, there were indications that the 
completeness of the data on childhood cancers and haematological malignancies was 
considerably lower than the estimates for all age groups and all sites of cancer. In the 
childhood leukaemia study, completeness was estimated to be 95.5% for the Nether-
lands and 96.4% for the catchment area of the IKL cancer registry. These results are no 
different from the overall estimates made in the IKL study. 
Owing to the fact that the procedures at most regional cancer registries are the same, it 
is likely that the results of the IKL study can be applied to the central Netherlands 
cancer registry. However, these good results can only be maintained with continuous 
effort. Diagnostic changes, changes in the assignment of tasks within health care (e.g., 
the proportion of patients treated by the general practitioner only) or the attentiveness of 
cancer registries can cause shifts in the completeness of case ascertainment. The 
method used in the IKL study cannot be conducted on a routine basis, it is too time-
consuming and requires considerable effort. However, knowledge of completeness over 
longer periods of time is important to interpret trends in cancer incidence against time. 
The capture-recapture method seems to be an attractive quality-control alternative. By 
recording the data sources of every record, it is possible to estimate the number of 
missed cases. In the application of capture-recapture methods, several assumptions 
must be made [6,7]. First, the number of records that have zero chance of being 
presented to the cancer registry cannot be estimated [8]. For example, the number of 
patients that are treated by a general practitioner without microscopic confirmation of 
the diagnosis and without referral to a hospital cannot be estimated with this method. 
Second, the capture-recapture method requires that data are obtained from independ-
ent sources (i.e., the probability of being captured by the separate data sources is not 
subject to correlation). A positive correlation would lead to underestimation of the 
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number of missed cases, while a negative correlation would lead to the opposite [9]. 
This independence, however, has to be assumed on the basis of knowledge of data 
sources. The method will be unsatisfactory for the continuous monitoring of complete-
ness. Deficiencies in completeness will probably occur at specific hospitals and apply to 
specific tumour sites. To be able to investigate such deficiencies, a large number of 
strata with small numbers of cases have to be analysed, which will mean a loss of 
power. Consequently, it is unlikely that deficiencies in notification procedures will be 
detected in time by the capture-recapture methods. 
Validity is considered to be another pivotal aspect in the data quality of a cancer 
registry. Validity and reproducibility in the Netherlands cancer registry are already 
receiving a great deal of attention. Reproducibility is tested on a nation-wide basis every 
two years by asking the tumour registrars to code a number of standard cases. These 
tests provide information about the extent to which coding rules are applied in a uniform 
manner. However, it does not give a true estimate of the proportion of errors in the 
cancer registry, because the cases are selected and the tumour registrar is aware of the 
aim of the tests. 
Questions put forward by clinicians about the ability of tumour registrars to collect in-
formation about cancer from clinical files formed the incentive to perform the study 
described in this thesis. As a recoding study would not be able to settle this matter 
adequately, we had to choose another study design. Twenty clinicians were asked to 
provide data on a small sample of their own patients by completing special cancer 
registry forms. However, it soon became clear that the data from the clinicians could not 
be used as a golden standard, because clinicians and registration personnel collect 
data for entirely different reasons. Whereas clinicians use their data to make decisions 
about treatment and to assess the prognosis, registration personnel aim to accomplish 
uniformity with the help of strict coding rules. Therefore, this study measured only relat-
ive validity. Nevertheless, there was close agreement between the data collected by the 
tumour registrars and the clinicians. 
The results of the three above-mentioned studies support the conclusion that the quality 
of the Netherlands cancer registry is high. Continuous effort will be required to maintain 
these high standards. Simple solutions to monitor the completeness of case 
ascertainment over time do not exist. Studies that use the independent case 
ascertainment method should be repeated at intervals. 
Recoding studies will have to be continued. These studies yield important information 
with respect to the uniformity of nation-wide coding. Also, repeating these studies will 
stimulate alertness for mistakes and coding errors. Studies that aim to measure validity, 
should be designed carefully and pay due attention to the golden standard. Data from 
independent clinical studies can be used for this purpose and the approach is cost-
effective. Examples are a study on the accuracy and completeness of data regarding 
childhood leukaemia [5] and a study on the validity of lung cancer staging [10]. 
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Use of cancer registry data 
In Chapter 5 the incidence rates of the regional cancer registry IKL are presented for the 
incidence years 1986-1988. These incidence rates have also been accepted for publica-
tion In volume VI of Cancer Incidence in Five Continents, as the first data from the new 
regional cancer registries in the Netherlands [11]. 
The incidence rates of cancer are comparable with the rates published by the regional 
cancer registry IKZ [12]. In comparison with reports from other cancer registries in 
Europe, the incidence of lung cancer and pleural mesothelioma in males and breast 
cancer in females is fairly high. Conversely, the incidence of lung cancer in females is 
(still) low. 
Descriptive cancer registry data can also be used to obtain clues about cancer etiology. 
Cancer incidence data from 1989 to 1991 inclusive, were obtained from the Netherlands 
Cancer Registry to study differences in cancer incidence according to the degree of 
urbanization. In males, there was no urban excess of tobacco related cancer, but there 
were urban-rural differences in cancer incidence for other sites and for tobacco-related 
cancer in females. It was also striking that the incidence rates of cancers with a viral 
factor in the etiology (liver cancer, cervical cancer and Kaposi's sarcoma) were 
increased in urban areas. Differences in the prevalence of life-style factors may still be 
large enough to cause variation in cancer incidence. The relation between exposure 
and outcome was studied ecologically, on a population level. It was not possible to take 
individual variation in exposure into account. Furthermore, urbanization only forms an 
approximation of the real exposure of interest (e.g. life-style factors, occupation, envir-
onmental pollution). For example, a recent Danish study demonstrated that urban-rural 
differences in the incidence of lung cancer disappeared almost completely after cor-
rection for smoking, occupation and type of dwelling [13]. 
Cancer registries often use age-adjusted incidence rates (e.g. using the World Standard 
Population) in order to be able to compare data reflecting only a single figure per popu-
lation. The cumulative rate and cumulative risk have been propagated as alternatives 
for age-adjusted rates. They both measure the risk that an individual will develop cancer 
[14]. In our study, we demonstrated that these measures overestimated the risk of 
developing cancer at an advanced age, because they disregarded the fact that the 
elderly run a greater risk of dying from a competing causes. More realistic cancer risk 
estimates can be obtained using life-expectancy tables. However, the method cannot 
replace age-adjusted incidence rates, because the life-table risk depends on life expect-
ancy. The life-table method has been used to make realistic estimates of the cancer risk 
for an individual [15] and to calculate the risk of prostate cancer in men with a positive 
family history [16]. The usefulness of the risk estimates for educating the public can be 
enhanced by also presenting risk estimates for periods of five or ten years from a given 
age [17]. 
Discussion 103 
Clinical study on breast cancer 
In 1982 the Breast Cancer Work Group started a study on the treatment of early breast 
cancer (stages l-lll) with the aim of introducing and monitoring breast-sparing surgery 
and of determining the impact of high-dose medroxyprogesterone acetate (MPA) on the 
results of adjuvant chemotherapy [18,19]. 
The data obtained were used to answer two secondary research questions: 
- does high-dose MPA influence the incidence of contralateral breast cancer? 
- do some etiological risk factors of breast cancer also influence the prognosis? 
Analysis of the results of the study demonstrated that high-dose MPA may protect 
against the occurrence of a second primary malignancy in the contralateral breast in 
postmenopausal women. In premenopausal women who received MPA there was a 
non-significantly increased risk of contralateral breast cancer. However, the number of 
events in both groups was small and the estimates were obtained in a subgroup 
analysis. This is a typical problem in these types of clinical trial, as they often have 
insufficient power to study rare events, such as second primary malignancies [20]. 
A more optimal design to study the effect of high-dose MPA on the incidence of breast 
cancer would be a case-control method that uses the Netherlands cancer registry for 
the selection of cases and controls. From the 1960s onwards many patients with 
endometrial cancer have received high-dose MPA [21]. By determining the dose 
administered and the duration of treatment with MPA in patients with endometrial 
cancer with or without subsequent breast cancer, it will be possible to confirm or refute 
our results. A comparable study on endometrial cancer following breast cancer treated 
with tamoxifen has shown that the Netherlands cancer registry can be used to conduct 
such a study efficiently [22]. 
Finally, the data of the study were used for another secondary analysis: to investigate 
the potential effect of known etiologic risk factors such as age at menarche, age at 
menopause, age at first pregnancy, use of oral contraceptives and family history on 
breast cancer prognosis. This study provided little support for the hypothesis that risk 
factors of breast cancer are also related to survival. 
Potential uses for cancer registration data 
In a relatively short period, a cancer registration system of high quality has been estab-
lished in the Netherlands. Epidemiologists have discovered various uses for cancer 
registry data and have started and completed several case-control and cohort studies. 
Data from the cancer registry have also been used to evaluate presumed clusters of 
cancer. 
So far, clinicians seem to have made less extensively use of cancer registry data. This 
can partly be explained by the fact that clinicians have direct access to their own 
patients' data. However, the use of cancer registry data also has advantages for 
clinicians. Data can be used during the planning of clinical trials [e.g. 23], for the selec-
tion of patients for (retrospective) studies and for the evaluation of diagnostic and 
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treatment guidelines. The main advantage of using cancer registry data is that the 
information is population-based, without selection with respect to e.g. prognosis. Clinical 
use of cancer registry data can be promoted by informing clinicians about their own 
patients in regular reports issued by the cancer registry. 
The former Netherlands Cancer Registry was closed down in 1974 because of low 
completeness and the fact that the data were hardly ever used. With respect to these 
criteria, the current position of the cancer registry is considerably better. However, 
continuation may be threatened by other factors. Recent legislation with respect to 
privacy (WPR: Wet persoons registratie) and the relation between patients and physi-
cians (WGBO: Wet op de geneeskundige behandelings overeenkomst) may hamper 
cancer registration. Both completeness and data quality may decrease if these laws are 
enforced without any compromise. The WGBO does leave some scope to perform 
medical research (e.g., exceptions when personal identifiers are encrypted), but it is not 
clear yet whether these changes will permit cancer registration to continue on an 
acceptable level. 
The usefulness of the cancer registry will increase even more, when complete survival 
information can be linked to the available information with respect to the incidence of 
cancer. Collection of survival information requires considerable effort. The information 
that can be collected from clinical files is often inadequate, as patients can be lost to 
follow-up through referral to other medical specialists or nursing homes. Also, the 
information with respect to patients treated at home by their general practitioner is not 
always passed on to the medical specialist. This method of data collection generally 
results in a large proportion of missing data. An advantage, however, is the fact that 
data on cause-specific mortality can be collected, but owing to the heavy workload 
required to collect complete follow-up data, the procedure is only used in specific 
projects. 
Connection with the automated population registry (GBA: Gemeenschappelijke Basis 
Administratie) is being investigated at present, but it is too soon to be certain about the 
outcome. The GBA has been asked to submit data on all deaths to the Netherlands 
Cancer Registry. By record linkage, it can be determined which cancer patients have 
died. For persons not linked, it has to be assumed that they are still alive. This 
procedure is cost-effective, but not optimal. For example, errors in personal identifiers 
will result in false-negative results. Also, the actual cause of death remains unknown. If 
survival is investigated, mortality from other causes has to be adjusted for by using the 
relative survival method [24]. In this method, area-specific life-expectancy tables have to 
be used to adjust the survival rates. 
Only the regional cancer registry IKZ has been able to collect virtually complete survival 
information with the aid of the municipal population registries [25]. However, because of 
current privacy regulations, this is not an option for the other regional cancer registries. 
The set of data items collected by the cancer registry has been in use since 1984 [26]. 
After ten years of registration it would be worthwhile to evaluate the data set and to 
investigate whether any items should be deleted or added. Several suggestions for 
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additional items have been made, such as co-morbidity and performance status [27,28], 
occupation and education [29,30] and race. Co-morbidity is a useful item in the study of 
treatment choice and survival. For example, to evaluate the effect of age on treatment 
choice, it is necessary to have information about co-morbidity. Experience of the IKZ 
cancer registry has shown that it is possible to collect data on this item [27]. Perform-
ance status is a measure of the physical condition of the patient. It is an important 
determinant of treatment choice and a strong predictor of survival [28]. However, it may 
not be possible to collect this information routinely from clinical files, because only a few 
clinicians make a note of this item. 
Recording of occupation and education has been advocated to be able to study survival 
[29]. Occupation and education may be considered to form proxy variables for socio-
economic status. However, these items are not generally recorded in clinical files. Also, 
many patients will be of retirement age or older when they become ill [30]. Recording a 
patient's profession may provide information that is useful for investigating the etiology 
of cancer. This would require extensive recording of the occupational history, preferably 
with information about possible exposure to carcinogens. It is unlikely that this informa-
tion will have been entered routinely into clinical files. Moreover, it is likely that only 
known risks will be confirmed (e.g., asbestos exposure and mesothelioma). To evaluate 
socio-economic status and survival (or occupation and etiology of cancer) the exposure 
variable must be collected with great care; this can only be accomplished optimally in 
dedicated studies in collaboration with the cancer registry. These exposures will need to 
be collected validly and completely to derive accurate results [30]. 
The decision to exclude in-situ cervical cancer from the national cancer registry (N.B. 
most regional cancer registries record this diagnosis) should be reconsidered. Exten-
sion of the range of recorded malignancies is necessary if cancer registration data are 
to be used in the evaluation of the cervical cancer screening programmes. 
Finally, the future of cancer registration lies in continued collaboration between 
clinicians and epidemiological researchers and in collaborative clinical epidemiological 
study designs. Fortunately, many clinical studies are on-going or have been planned. 
The regional cancer registry IKO is involved in projects such as recording the myelo-
dysplasia syndrome (MDS), evaluating prognostic factors in low-grade astrocytomas (in 
cooperation with the IKL and IKZ), evaluating the treatment and prognosis of stage MIA 
non-small cell lung cancer and evaluating the guidelines for the diagnosis and treatment 
of Hodgkin's disease. The regional cancer registry IKL is involved in projects such as 
the evaluation of treatment choice in lung cancer according to age, prognostic factors in 
breast cancer (Breast Cancer Work Groups of the IKL and IKO) and the hospital 
oncology committees. Participation of the cancer registries in these studies varies from 
patient selection to active data collection and statistical analysis. 
Over the years, the impact of cancer in Western society has changed immensely. At the 
beginning of this century, cancer was not as frequent as it is today and many of today's 
most common cancer sites were seldom affected [31] The differences over time can be 
attributed to the short life expectancy in 1900, improved detection and changing 
exposure to carcinogens. However, remarkable trends in time have also been observed 
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recently for specific forms of cancer. It is therefore not difficult to imagine that within a 
few decades, the manifestation of cancer will have changed again. Cancer is not one 
disease, but a collection of maybe more than 200 different types of malignancy. In most 
of these types, knowledge is limited with respect to etiology, treatment and prognosis. 
Cancer registration is a powerful tool for monitoring trends and promoting the necessary 
clinical and epidemiological research. 
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SUMMARY 
The Netherlands re-established a nation-wide cancer registry in 1989. Cancer 
registration is an essential part of cancer control. The data can be used for many pur-
poses, such as etiological research, prevention and evaluation of patient care. The use 
of cancer registry data justifies its collection. However, the data are only worthwile if 
they are of sufficiently high quality. Two aspects of data quality are considered: com-
pleteness of case ascertainment and validity (Chapter 1). 
The completeness of cancer registration of the IKL regional cancer registry was studied 
for 1988-1990 by means of the independent case ascertainment method. The study was 
performed using a centralized database of general practitioners (GP), with their patients' 
background variables and diagnoses. The IKL cancer registry had recorded 307 out of 
the 319 eligible malignancies (96.2%). Five out of the 12 missed cases could be 
attributed to systematic shortcomings in the notification procedures (e.g. patient treated 
by their GP only). Earlier warnings from GPs that the Netherlands Cancer Registry 
would have a high incompleteness rate because of systematic deficiencies in the 
notification procedures, were therefore unjustified. The estimated completeness of the 
IKL cancer registry for all malignancies was comparable with the rates reported by 
cancer registries with a longer history outside the Netherlands (Chapter2). 
An alternative and efficient method to estimate the completeness of a cancer registry is 
the capture-recapture method. Data from three regional cancer registries (IKL, IKMN 
and IKO) were used to investigate whether this method can be applied on a routine 
basis. The results indicated a very high degree of completeness, estimated at 98.3%. 
The estimates of completeness were the lowest for malignancies of the skin, lymphatic 
and haematopoietic tissue, other or unknown sites and for the age group > 75 years. 
A major drawback of the capture-recapture method, however, is its inability to estimate 
the number of cases that one or both data sources do not notify the registry about 
routinely. Another limitation is the lack of statistical power to detect incompleteness at 
an early stage. It is concluded that the capture-recapture method is not useful for every-
day monitoring of the completeness of cancer registration (Chapter 3). 
To investigate the quality of the data recorded by the IKL cancer registry a study was 
performed with the aim of comparing data supplied by clinicians to data collected by the 
registration personnel. Twenty clinicians reabstracted the information from a random 
sample of about ten of their patients, who were diagnosed with cancer in 1989 or 1990. 
After coding, the information was compared to that in the cancer registry records. 
Information on 190 cases was available for comparison purposes. The relative 
frequency of major disagreements was 0% for date of birth, 0% for gender, 5% for date 
of incidence, 6% for primary site, 2% for laterality, 2% for histological type and 2% for 
behaviour code. Disagreements could be attributed to the handling of different coding 
rules (e.g. incidence date), or to a lower level of precision by the clinician in comparison 
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with the registration personnel (e.g. primary site). In general, the data of the cancer 
registry seemed to be very accurate (Chapter 4). 
In Chapter 5 incidence rates are presented from a Dutch cancer registry that has been 
established only recently. From 1986 to 1988 a total of 8409 new malignancies were 
recorded by the IKL cancer registry (4550 in males and 3859 in females); non-
melanoma skin cancer and non-infiltrating malignancies were excluded. In males, lung 
cancer was the most common cancer site with an annual incidence rate of 83.5 per 
100,000 (world standard population), followed by cancer of the prostate (29.7), colon 
(19.8), stomach (16.8), rectum (16.4) and urinary bladder (11.1). In females, breast 
cancer was the most common malignancy with an incidence rate of 68.4 per 100,000, 
followed by cancer of the colon (17.2), corpus uteri (10.6), rectum (10.3), lung (9.2) and 
ovary (9.0). The world standardised rate for total cancer was 274.0 in males and 195.7 
in females. 
The lung cancer incidence rate in men in the IKL cancer registry was high in compar-
ison with other European cancer registries. Only the cancer registries in the United 
Kingdom and the cancer registry in Eindhoven have reported comparable rates. The 
incidence rate of lung cancer in females is fairly low. In the IKL area the incidence rate 
of pleura mesothelioma was fairly high in comparison with the other cancer registries in 
Europe (Chapter 5). 
Cancer incidence data from 1989 to 1991 inclusive were obtained from the Netherlands 
Cancer Registry to study differences in cancer incidence rates between urban and rural 
communities. With increasing urbanization, slightly higher incidence rates were 
observed for all cancer sites combined (rate ratio [RR]= 1.08 in males and 1.12 in 
females). Statistically significant RRs of > than 1.4 were observed for Kaposi's sarcoma 
(m), mesothelioma (m), cancer of the liver (m), mouth/pharynx (m+f), oesophagus (f), 
larynx (f), lung (f), other respiratory organs (f), cervix (f) and Hodgkin's disease (m). 
Significantly lower incidence rates were found in urban areas for non-melanoma of the 
skin (m+f) and cancer of the lip (m). In males, the urban excess of tobacco-related 
cancer had largely disappeared. However, urban-rural differences in cancer incidence 
still existed for other cancer sites and for tobacco-related cancer in females. Apparently, 
differences in the prevalence of lifestyle factors are still large enough to cause variation 
in cancer incidence (Chapter 6). 
In epidemiology and cancer registration, several algorithms can be used to calculate the 
risk of cancer. Since the publication of the third volume of Cancer Incidence in Five 
Continents (in 1976) the use of the cumulative rate has been propagated as an altern-
ative for other age-standardized incidence rates and as an approximation of the cumu-
lative risk, when the risk is small. However, this risk estimate is a conditional risk; it is 
based on the assumption that an individual will not die from another cause, before the 
age of, for example, seventy-five years. Owing to this condition, the cumulative risk 
overestimates the risk at advanced age. It is possible to make a more accurate estimate 
of the risk that an individual will develop cancer by using life expectancy tables. The 
resulting life-time risk does take competing causes of death into account. 
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Lifetime risks were calculated according to the different methods using cancer incidence 
data from the comprehensive cancer centre IKL (Maastricht), region-specific death rates 
and life tables from the Netherlands Central Bureau of Statistics. The lifetime risk of 
developing cancer was estimated to be 34.8% for males and 30.4% for females. In 
males especially, the risk estimates were considerably higher when the cumulative risk 
method was used. The life table method was convenient for estimating the probability 
that a person will develop cancer during a defined period or during his or her life. The 
other methods overestimated the risk of the disease under investigation, especially in 
the elderly (Chapter 7). 
In the last two chapters, results are presented from a clinical study started by the IKL 
Breast Cancer Work Group in cooperation with the cancer registry. 
First the effect was studied of high-dose Medroxyprogesterone Acetate (MPA) on the 
risk of contralateral breast cancer (CLBC). In a group of 866 patients, 403 had node-
negative breast cancer and were treated with surgery and radiotherapy (if indicated). 
The remaining 463 patients with node-positive breast cancer underwent surgery, 
radiotherapy and adjuvant chemotherapy (FAC). Randomization determined whether 
high-dose MPA was added to the adjuvant chemotherapy (N=229) for a duration of six 
months (with a total dose of 36,000 mg). In the group of 866 breast cancer patients, 51 
cases of CLBC were diagnosed after a median follow-up of 6.5 years (no FAC: 29 
cases; FAC without MPA: 14 cases; and FAC with MPA: 8 cases). Histological review of 
both tumours by one pathologist yielded definitive evidence that 45 out of the 51 CLBCs 
were new primary breast cancers. High-dose MPA added to FAC protected against the 
risk of CLBC (RR 0.5, 95% CI 0.2-1.3). When the data were analysed separately for 
pre- and post-menopausal women, a heterogenous effect was observed. The protective 
effect was restricted to post-menopausal women (RR 0.2, 95% CI 0.04-0.8), while in 
pre-menopausal women the RR of high-dose MPA was estimated at 1.9 (95% CI 
0.6-6.4). Owing to the small number of cases in this study, further confirmation of the 
results is needed. Important issues are whether the effect of MPA is related to dose and 
whether the effect will persist over time (Chapter 8). 
Several risk factors for the etiology of breast cancer have been correlated with the 
prognosis of breast cancer. However, the studies report conflicting results. 
In our study, age at menarche, parity, age at menopause and family history were not 
consistently related to survival. Young age at first full-term pregnancy was related to 
decreased survival (RR 1.69, 95% CI 1.04-2.68). Use of oral contraceptives was not 
correlated with survival (RR 1.10, 95% CI 0.80-1.51) nor was family history (RR 0.93, 
95% CI 0.66-1.30). This study provided little support for the hypothesis that risk factors 
for breast cancer are related to survival (Chapter 9). 
In a relatively short period, a cancer registry of high quality has been established in the 
Netherlands. Not only epidemiologists, but also clinicians and other investigators have 
discovered the several potentials of using cancer registry data. The present structure 
and outlines of the cancer registry have been valid since 1984. It seems to be time to 
112 Summary 
reconsider the data set and to consider the extension or deletion of some items. Use of 
cancer registration can be promoted further by conducting clinical studies in cooperation 
with clinicians (Chapter 10). 
113 
SAMENVATTING 
Kankerregistratie: kwaliteit van gegevens en gebruiksmogelijkheden 
Sinds 1989 heeft Nederland weer een landelijke kankerregistratie. Kankerregistratie is 
een wezenlijk onderdeel van de kankerbestrijding. De informatie van deze registratie 
kent vele toepassingen: bijvoorbeeld onderzoek naar oorzaken van kanker, onderzoek 
naar mogelijkheden om kanker te voorkómen en evaluatie van de behandeling van 
kanker. Slechts een daadwerkelijk gebruik van de gegevens rechtvaardigt het instand-
houden van de registratie. Echter, de gegevens zijn alleen bruikbaar als deze van 
voldoende kwaliteit zijn. Twee aspecten van de kwaliteit worden onderscheiden: 
compleetheid van gegevensverzameling en validiteit (Hoofdstuk 1). 
De compleetheid van de gegevensverzameling in de periode 1988-1990 van de regio-
nale kankerregistratie IKL (Integraal Kankercentrum Limburg) werd bestudeerd door 
vergelijking te trekken van deze registratie met een ander onafhankelijk bestand van 
gegevens over kanker. In deze studie werd gebruik gemaakt van het bestand van het 
Registratienetwerk Huisartspraktijken (RNH). De regionale kankerregistratie IKL had 
307 van de 319 daar voor in aanmerking komende gevallen van kanker ook daadwerke-
lijk geregistreerd (96,2%). Vijf van de 12 gemiste gevallen van kanker waren gemist 
door systematische tekortkomingen in de signaleringsprocedures van de registratie 
(bijvoorbeeld een patiënt die alleen bekend was bij de huisarts). Hierdoor is gebleken 
dat eerdere waarschuwingen van huisartsen, dat de Nederlandse kankerregistratie in 
hoge mate incompleet zou zijn door dergelijke systematische tekortkomingen, onterecht 
waren. De geschatte compleetheid voor kanker-totaal van de regionale kanker-
registratie IKL is vergelijkbaar met die van andere goede buitenlandse kanker-
registraties (Hoofdstuk 2). 
Een alternatieve en wellicht efficiënte methode om de compleetheid van een kanker-
registratie te bepalen is de zogenaamde capture-recapture ('vangst-hervangst') 
methode. Gegevens van drie Nederlandse regionale kankerregistraties (IKL, IKMN en 
IKO) werden gebruikt om te onderzoeken of deze methode ook inderdaad te benutten is 
om de compleetheid van de registratie doorlopend te bewaken. De resultaten duiden op 
een hoge mate van compleetheid, te weten 98,3%. De compleetheid was het laagst 
voor huidkanker, kwaadaardige nieuwvormingen van lymfeklieren en leukemieën, 
kanker met onbekende of overige lokalisaties en voor kankerpatiënten ouder dan 75 
jaar. 
Een belangrijk nadeel van de capture-recapture methode is echter dat de methode niet 
het aantal gevallen van kanker kan schatten die niet gemeld worden door één of beide 
signaleringsbronnen van de kankerregistratie. Ook is de capaciteit van de methode om 
incompleetheid vroegtijdig te signaleren zeer beperkt. Geconcludeerd wordt daarom dat 
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de capture-recapture methode niet bruikbaar is als continue bewaking van de compleet-
heid van de kankerregistratie (Hoofdstuk 3). 
Om de gegevenskwaliteit van de regionale kankerregistratie IKL te onderzoeken is een 
studie opgezet waarbij gegevens geleverd door medisch specialisten werden verge-
leken met de gegevens verzameld door registratiemedewerkers. Twintig medisch spe-
cialisten noteerden informatie van een willekeurige steekproef van tien patiënten uit hun 
praktijk, bij wie de diagnose kanker in 1989 of 1990 was gesteld. Na codering werd 
deze informatie vergeleken met die van de kankerregistratie. 
Uiteindelijk konden de gegevens van 190 patiënten met kanker worden beschouwd. Het 
percentage verschillen was respectievelijk 0% voor geboortedatum, 0% voor geslacht, 
5% voor diagnosedatum, 6% voor lokalisatie, 2% voor lateralisatie, 2% voor histologie 
en 2% voor maligniteitsgraad. Deze verschillen konden worden toegeschreven aan 
verschillen in toepassing van coderingsregels tussen specialisten en registratie-
medewerkers of aan een mindere mate van precisie door specialisten bij het invullen 
van de formulieren. In het algemeen waren de gegevens van de kankerregistratie als 
zeer goed te kwalificeren (Hoofdstuk 4). 
In hoofdstuk 5 worden incidentiecijfers gepresenteerd van de regionale kankerregis-
tratie IKL. Van 1986 tot en met 1988 werden in het totaal 8409 nieuwe gevallen van 
kanker geregistreerd (4550 bij mannen en 3859 bij vrouwen); met uitzondering van niet-
melanomen van de huid en niet-invasieve (in-situ) gevallen van kanker. Bij mannen was 
longkanker de meest voorkomende vorm van kanker met een incidentiecijfer van 83,5 
per 100.000 persoonsjaren (toegepast op de leeftijdsopbouw met de wereld standaard 
bevolking), gevolgd door prostaatkanker (29,7), kanker van de dikke darm (19,8), 
maagkanker (16,8), endeldarmkanker (16,4) en blaaskanker (11,1). Bij vrouwen was 
borstkanker de meest voorkomende vorm van kanker met een incidentiecijfer van 68,4 
per 100.000 persoonsjaren, gevolgd door kanker van de dikke darm (17,2), baar-
moederlichaamkanker (10,6), endeldarmkanker (10,3), longkanker (9,2) en eierstok-
kanker (9,0). Het gestandaardiseerde incidentiecijfer (wereld standaard bevolking) voor 
alle vormen van kanker gezamenlijk bedraagt 274,0 voor mannen en 195,7 voor 
vrouwen. 
De incidentie van longkanker bij mannen in de regio van de regionale kankerregistratie 
IKL is hoog in vergelijking met de incidentiecijfers van andere Europese registraties. 
Alleen de kankerregistraties in Groot-Brittannië en de IKZ-registratie (Eindhoven) 
rapporteren vergelijkbare incidentiecijfers voor longkanker. Het incidentiecijfer voor 
longkanker bij vrouwen is verhoudingsgewijs juist laag. Ook de incidentie van longvlies-
kanker (mesothelioom) is hoog in de IKL-regio vergeleken met andere Europese 
registraties (Hoofdstuk 5). 
Kankerincidentiecijfers m.b.t. de incidentiejaren 1989 tot en met 1991 werden verkregen 
van de landelijke kankerregistratie om verschillen in incidentie te bestuderen tussen 
stad en platteland. Gemeentes met de hoogste mate van verstedelijking hadden gemid-
deld hogere incidentiecijfers voor alle vormen van kanker gezamenlijk (rate ratio van 
1,08 voor mannen en 1,12 voor vrouwen) dan plattelandgemeentes. Statistisch signi-
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ficant verhoogde rate ratios van tenminste 1,4 werden waargenomen voor het Kaposi 
sarcoom (bij mannen), kanker van het longvlies (m), de lever (m), de mondholte en keel 
(m+v), de slokdarm (bij vrouwen), het strottehoofd (v), de long (v), de overige adem-
halingsorganen (v), de baarmoederhals (v) en de ziekte van Hodgkin (m). Statistisch 
significant verlaagde rate ratios werden waargenomen voor huidkanker (exclusief het 
melanoom; m+v) en lipkanker (m). De verhoogde incidentie van aan tabak gerelateerde 
vormen van kanker in de stad is kennelijk verdwenen. Toch bestaan er nog verschillen 
in kankerincidentie tussen stad en platteland en voor aan tabak gerelateerde vormen 
van kanker bij vrouwen. Kennelijk zijn de verschillen in leefgewoonten tussen stad en 
platteland nog voldoende groot om verschillen in kankerincidentie te veroorzaken 
(Hoofdstuk 6). 
In de epidemiologie en bij kankerregistraties worden verscheidene methodes gebruikt 
om de kans op kanker voor een individu te berekenen. Sedert de verschijning van het 
derde deel van 'Cancer Incidence in Five Continents' wordt de cumulatieve incidentie 
('cumulative rate') gepropageerd als alternatief voor het gestandaardiseerde incidentie-
cijfer en als schatting van het cumulatief risico ('cumulative risk'), als het cumulatief 
risico klein is. Echter, deze risicoschattingen betreffen in wezen voorwaardelijke 
kansen; er wordt vanuit gegaan dat een individu voor een zekere leeftijd (bijvoorbeeld 
75 jaar) niet aan een andere doodsoorzaak zal komen te overlijden. Dit betekent dat de 
cumulatieve incidentie en het cumulatief risico de kans op kanker op hoge leeftijd zal 
overschatten. Het is echter mogelijk een accurate kans op kanker te berekenen door 
gebruik te maken van overlevingstafels. De daarmee berekende kans op kanker houdt 
rekening met de kans om aan een andere ziekte te overlijden. 
Gebruikmakend van deze methode werd de kans op kanker gedurende het leven bere-
kend met behulp van kankerincidentiecijfers van de regionale kankerregistratie IKL en 
overlevingstafels van het Centraal Bureau voor de Statistiek. De kans op kanker 
gedurende het leven bedroeg 34,8% voor mannen en 30,4% voor vrouwen. De over-
levingstafeltechniek is een geschikte methode om de kans op kanker gedurende een 
bepaalde periode of het hele leven te schatten. Andere methoden overschatten de kans 
op kanker met name op hogere leeftijd (Hoofdstuk 7). 
In de laatste twee hoofdstukken van het proefschrift worden gegevens geanalyseerd, 
verkregen van een klinische studie die was opgezet door de IKL tumorwerkgroep Borst-
kanker in samenwerking met de Kankerregistratie. 
Allereerst is het effect bestudeerd van hoge dosis medroxyprogesterone acetaat (MPA) 
op de incidentie van een nieuw geval van kanker in de andere borst. Van de 866 
patiënten met borstkanker, werden 403 patiënten zonder uitzaaiingen in de lymfeklieren 
operatief behandeld en indien nodig met radiotherapie. De resterende 463 patiënten 
met uitzaaiingen in de lymfeklieren werden behandeld met een operatie, aanvullende 
chemotherapie en indien nodig radiotherapie. Door loting werd bepaald dat 229 van 
deze vrouwen tevens een hoge dosis MPA kregen gedurende zes maanden (totale 
dosis 36000 mg). In de totale groep van 866 patiënten met borstkanker werd bij 51 
patiënten na een gemiddelde duur van 6,5 jaar kanker in de andere borst ontdekt. Bij 
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histologische controle van het eerste en het tweede geval van borstkanker bleek dat bij 
45 van de 51 patiënten de tweede tumor een daadwerkelijk nieuw geval van kanker 
betrof. 
Een hoge dosis M PA toegevoegd aan de aanvullende chemotherapie beschermde 
tegen kanker in de andere borst (rate ratio [RR]=0,5 met 95% betrouwbaarheidsinterval 
[95% BI]: 0,2-1,3). Analyse van de pre- en de postmenopausal vrouwen afzonderlijk, 
leverde aanmerkelijk verschillende resultaten op. Het mogelijk beschermende effect van 
een hoge dosis MPA was beperkt tot de postmenopausale vrouwen (RR=0,2; 95% BI: 
0,04-0.8), terwijl bij premenopausal vrouwen de RR van een hoge dosis MPA 1,9 
bedroeg (95% BI: 0,6-6,4). Vanwege de kleine aantallen in deze studie is nadere beves-
tiging van deze uitkomsten noodzakelijk. Daarbij moet dan ook onderzocht worden of 
het effect afhankelijk is van de hoogte van de dosis en van de toedieningsduur van 
MPA (Hoofdstuk 8). 
Verscheidene risicofactoren voor het ontstaan van borstkanker zijn ook in verband 
gebracht met het verdere verloop van de ziekte. De resultaten van de gepubliceerde 
studies zijn echter op vele punten in tegenspraak met elkaar. 
In deze studie bleken leeftijd bij de eerste menstruatie, het aantal kinderen, leeftijd bij 
de overgang en het vóórkomen van borstkanker in de familie niet gerelateerd te zijn aan 
de overleving. Het op jonge leeftijd krijgen van het eerste kind bleek samen te hangen 
met een verminderde kans op overleving (RR=1,69; 95% BI: 1,04-2,68). Gebruik van de 
'pil' (orale anticonceptiva) was niet gerelateerd aan de kans op overleving (RR=1,10; 
95% BI: 0,80-1,51). Hetzelfde gold voor het vóórkomen van borstkanker in de familie 
(RR=0,93; 95% BI: 0,66-1,30). Deze studie leverde dus weinig bewijs op voor de theorie 
dat risicofactoren voor borstkanker ook in verband staan met de overleving van deze 
ziekte (Hoofdstuk 9). 
In een tamelijk korte periode is in Nederland een kankerregistratie opgezet van buiten-
gewoon goede kwaliteit. Niet alleen epidemiologen, maar ook medisch specialisten en 
andere onderzoekers hebben de diverse gebruiksmogelijkheden van de kankerregis-
tratie ontdekt. De huidige opzet van de kankerregistratie stamt al uit 1984. Het is 
daarom gewenst om de set van gegevens te evalueren en de mogelijkheid om de gege-
vensset uit te breiden, in te krimpen of aan te passen te overwegen. Het gebruik van de 
registratie kan verder bevorderd worden door klinisch studies op te zetten en uit te 
voeren in samenwerking met de medisch specialisten (Hoofdstuk 10). 
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nog steeds leveren) aan het verzamelen van de gegevens. Medisch specialisten en 
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Ook andere medewerkers van het IKL en IKO wil ik noemen: de automatiserings-
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aangenaam maken en mij voorzien van de fraaiste programma's en tabellen. De 
projectmedewerker bij het IKL, Marjan de Rijke, heeft mij reeds vele malen aangenaam 
verrast met goed uitgewerkte onderzoeksvoorstellen en analyses. Ik hoop dat onze 
samenwerking gecontinueerd kan worden. 
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completeren van de gegevensverzameling. Die samenwerking heeft al geresulteerd in 
de promotie van Pierre Hupperets en Jos Jager zal hopelijk spoedig volgen. 
Van een aantal artikelen in dit proefschrift is het Engels nauwgezet gecontroleerd door 
Judith Abma-Hill. Ik waardeer het zeer dat zij bij de correcties geen rood maar een 
zwart potlood gebruikt. Bij het nalezen van door Judith verbeterde artikelen valt mij 
telkens weer op hoe mooi Engels kan zijn. 
De samenwerking met Piet van den Brandt dateert al van 1987. Piet onderkende het 
belang van de kankerregistratie, maar met name ook het belang van een kwalitatief 
goede registratie. Zijn methodologische kennis en zijn vermogen de grote lijnen te 
onderscheiden heb ik altijd bewonderd. Ik hoop dat de samenwerking na januari weer 
verder uitgebouwd kan worden. 
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proefschrift behoorlijk verrijkt en lijn gebracht in de verschillende studies. Helaas 
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Ten slotte, Danielle, Irene en Tim. Niets is zo fijn als genieten van je familie: de groei en 
ontwikkeling van je kinderen. Eindelijk Irene: ze gaan 'vragen stellen' aan papa. 
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hoop dat ik meer tijd voor jullie krijg. 
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STELLINGEN 
behorende bij het proefschrift 
'Cancer registration: 
data quality and prospects for use" 
Leo Schouten 
Nijmegen, 17 december 1996 
1. De bruikbaarheid van een kankerregistratie hangt in belangrijke mate af van 
de kwaliteit van de gegevens (naar Robles, 1988). 
2. Door de goede infrastructuur van de Nederlandse gezondheidszorg en door 
de gekozen werkwijze (dat wil zeggen de gebruikte bronnen voor signalenng 
en het verzamelen van gegevens door daartoe opgeleide medewerkers) voor 
de registratie is in Nederland in korte tijd een kankerregistratie van goede 
kwaliteit opgebouwd (dit proefschrift). 
3. De enige rechtvaardiging voor het opzetten van een kankerregistratie is het 
daadwerkelijk gebruik van de gegevens (naar Saxen, 1980). 
4. BIJ koppeling van gegevens van een kankerregistratie met die van een 
cohortonderzoek kunnen beter te weinig dan teveel tumoren gerapporteerd 
worden (naar Riboh, 1996). 
5. In Nederland bestaan er nog steeds verschillen met betrekking tot de 
kankenncidentie tussen de stad en het platteland (dit proefschrift). 
6. Met behulp van sterftetafels is het mogelijk adequaat het nsico te berekenen 
om kanker te knjgen gedurende het leven (dit proefschnft). 
7. Om het voortbestaan van de Nederlandse kankerregistratie te garanderen, Is 
een wettelijke regeling met betrekking tot de privacy gewenst. 
8. In wetenschappelijke grafieken dient de verhouding van de inkt gebruikt om 
gegevens weer te geven tot de totale hoeveelheid gebruikte inkt (inclusief de 
inkt gebruikt ter verfraaiing van de grafiek) maximaal te zijn (naar Tufte, 1983). 
9. Als maar voldoende verschillende ziektes worden geanalyseerd, zal blijken dat 
elke plaats in Nederland een eigen ziektecluster heeft. 
10. Vergelijking van overlevingsgegevens van verschillende kankerregistraties Is 
weinig zinvol, zolang de verschillen in kwaliteit tussen de kankerregistraties 
groter zijn dan de verschillen in overleving. 
11. Dat het imago van de epidemiologie verbetering behoeft, blijkt uit het feit dat 
de spellingcontrole van Wordperfect suggereert het woord 'incidentie' door 
'Incidentje' te vervangen. 


